Dsrna molecules for regulating MASP2 gene activity

By interfering with MASP2 gene expression with a specific design, the problem of difficulty in regulating MASP2 activity in the prior art is solved, and effective treatment of MASP2 activity-related diseases is achieved, and a new treatment method is provided.

WO2024230836A1PCT designated stage expired Publication Date: 2024-11-14RONA THERAPEUTICS INC +3
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/092668
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-11
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate the activity of mannan-binding lectin-associated serine protease 2 (MASP2), leading to autoimmune disease and inflammatory responses, and the existing inhibitors have limited effect.

Method used

Using double-stranded RNA (dsRNA) to specifically reduce MASP2 gene expression through RNA interference mechanisms, and using small interfering RNA (siRNA) to inhibit MASP2 expression in cells, including the design of specific sense strands and antisense strand sequences to form complementary double strand regions , used to treat diseases related to MASP2 activity.

Benefits of technology

By reducing MASP2 expression, effectively inhibiting its activity, reducing the symptoms and pathological processes of related diseases, a new treatment is provided to prevent and treat MASP2-mediated diseases such as arthritis and IgA nephropathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024092668-FTAPPB-I100001
    Figure PCTCN2024092668-FTAPPB-I100001
  • Figure PCTCN2024092668-FTAPPB-I100002
    Figure PCTCN2024092668-FTAPPB-I100002
  • Figure PCTCN2024092668-FTAPPB-I100003
    Figure PCTCN2024092668-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a double-stranded RNA used to inhibit the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in cells, cells containing nucleotides encoding the same, and a method of using the dsRNA or cells to treat diseases or symptoms mediated or associated with MASP2 expression in subjects.
Need to check novelty before this filing date? Find Prior Art

Description

dsRNA molecules that regulate MASP2 gene activity Technical Field

[0001] The present invention relates to the field of RNA interference. Background Art

[0002] The complement system, composed of more than 30 plasma- and cell-bound proteins, plays an important role in innate and adaptive immunity. The proteins of the complement system function in a series of enzymatic cascades through multiple protein interactions and cleavage events.

[0003] The complement system is activated through three pathways: the classical pathway, the lectin pathway, and the alternative complement pathway. The classical pathway is typically triggered by host antibodies bound to foreign antigens and, therefore, requires exposure to antigen to produce a specific antibody response, making it part of the acquired immune system. The lectin pathway and the alternative complement pathway, on the other hand, are part of the innate immune system.

[0004] Mannan-binding lectin-associated serine protease-2 (MASP-2) participates in the lectin pathway of the complement system. Inhibition of MASP-2 does not interfere with the antibody-dependent classical complement activation pathway.

[0005] The gene encoding human MASP2 is located on human chromosome 1p36.22 and is designated MASP2. The propeptide encoded by this gene undergoes proteolysis to produce A and B chains, which then heterodimerize to form the mature 76 kDa serine protease MASP2. MASP2 cleaves complement components C2 and C4 in the lectin pathway of the complement system to produce C3 convertase. The protease MASP2 also plays a role in the coagulation cascade by cleaving prothrombin to form thrombin. MASP-2 exhibits thrombin-like activity, and high concentrations of MASP-2 are associated with a future risk of venous thromboembolism. Inhibiting MASP2 levels protects against thrombosis. MASP2 is highly expressed in the liver. MASP2 is also present in the brain, gallbladder, heart, kidneys, and circulatory system. Alternative splicing of this gene produces multiple transcript variants, at least one of which encodes a proteolytically processed isoform, designated Map19, which is present in plasma.

[0006] Mannose-binding lectin 2 (MBL) activates MASP2 by changing its conformation. Activated MASP2 can initiate complement activation and kill target cells.

[0007] The complement system must be precisely regulated to selectively target invading microorganisms and avoid autoimmune damage (Ricklin et al., Nat. Immunol. 11:785-797, 2010). Abnormally regulated complement activity and unabated complement activity can lead to autoimmune diseases, causing unchecked inflammation and tissue destruction. Inappropriate activation of MASP2 can contribute to a number of diseases, including IgA nephropathy and arthritis.

[0008] Several inhibitors for inhibiting MASP-2 have been studied. Antibody inhibitors, such as the monoclonal antibody targeting MASP-2 disclosed in U.S. Patent No. 9,011,860, and small molecule inhibitors, such as the small molecule inhibitors of MASP-2 disclosed in WO2021113682A1 and WO2022096394A1, have been studied.

[0009] Therefore, there is a need in the art for compositions and methods for treating diseases, disorders, and conditions that would benefit from inhibition of MASP-2.

[0010] Reduction of MASP-2 expression by small interfering RNA (siRNA) based on an RNA interference mechanism is a novel approach for treating diseases, disorders, and conditions associated with MASP-2 activity.

[0011] Summary of the Invention

[0012] The present invention provides novel double-stranded RNA (dsRNA), cells, kits, and pharmaceutical compositions for inhibiting the expression of MASP2 in cells, as well as methods for inhibiting or reducing MASP2 gene expression or treating diseases or conditions that benefit from reduced MASP2 expression using the siRNA, cells, kits, or pharmaceutical compositions.

[0013] In a first aspect, the present invention provides a double-stranded nucleotide sequence (dsRNA) for inhibiting the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a cell, the dsRNA comprising a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand and the antisense strand are each independently 15-30 nucleotides in length, and the antisense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 22-40. In some embodiments, the sense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 2-20.

[0014] In some embodiments, the length of the sense strand and the antisense strand is independently 17-27 nucleotides, preferably 18-25 nucleotides, more preferably 19-21 nucleotides. In some embodiments, the length of the sense strand is 15-27 nucleotides, preferably 17-25 nucleotides, more preferably 18-23 nucleotides, more preferably 19-21 nucleotides, and most preferably 19 amino acids. In some embodiments, the length of the antisense strand is 15-27 nucleotides, preferably 17-25 nucleotides, more preferably 18-23 nucleotides, more preferably 19-22 nucleotides, and most preferably 20 or 21 amino acids.

[0015] In some embodiments, the dsRNA is siRNA.

[0016] In some embodiments, the antisense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, a nucleotide sequence of at least 18 consecutive nucleotides, a nucleotide sequence of at least 19 consecutive nucleotides, or a nucleotide sequence of at least 20 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 22-40. Preferably, the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 22-40.

[0017] In some embodiments, the sense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, or a nucleotide sequence of at least 18 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 2-20, and preferably the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 2-20.

[0018] In some embodiments, the siRNA comprises any one of the following paired sense and antisense sequences:

[0019] (1) Sense strand: SEQ ID NO: 2, antisense strand: SEQ ID NO: 22;

[0020] (2) Sense strand: SEQ ID NO: 3, antisense strand: SEQ ID NO: 23;

[0021] (3) Sense strand: SEQ ID NO: 4, antisense strand: SEQ ID NO: 24;

[0022] (4) Sense strand: SEQ ID NO: 5, antisense strand: SEQ ID NO: 25;

[0023] (5) Sense strand: SEQ ID NO: 6, antisense strand: SEQ ID NO: 26;

[0024] (6) Sense strand: SEQ ID NO: 7, antisense strand: SEQ ID NO: 27;

[0025] (7) Sense strand: SEQ ID NO: 8, antisense strand: SEQ ID NO: 28;

[0026] (8) Sense strand: SEQ ID NO: 9, antisense strand: SEQ ID NO: 29;

[0027] (9) Sense strand: SEQ ID NO: 10, antisense strand: SEQ ID NO: 30;

[0028] (10) Sense strand: SEQ ID NO: 11, antisense strand: SEQ ID NO: 31;

[0029] (11) Sense strand: SEQ ID NO: 12, antisense strand: SEQ ID NO: 32;

[0030] (12) Sense strand: SEQ ID NO: 13, antisense strand: SEQ ID NO: 33;

[0031] (13) Sense strand: SEQ ID NO: 14, antisense strand: SEQ ID NO: 34;

[0032] (14) Sense strand: SEQ ID NO: 15, antisense strand: SEQ ID NO: 35;

[0033] (15) Sense strand: SEQ ID NO: 16, antisense strand: SEQ ID NO: 36;

[0034] (16) Sense strand: SEQ ID NO: 17, antisense strand: SEQ ID NO: 37;

[0035] (17) Sense strand: SEQ ID NO: 18, antisense strand: SEQ ID NO: 38;

[0036] (18) sense strand: SEQ ID NO: 19, antisense strand: SEQ ID NO: 39; and

[0037] (19) Sense strand: SEQ ID NO: 20, antisense strand: SEQ ID NO: 40.

[0038] In some embodiments, substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, or all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.

[0039] In some embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, and phosphorothioate internucleotide linkage modifications.

[0040] In some embodiments, the sense strand and / or the antisense strand comprises SCP modified nucleotides.

[0041] In some embodiments, the 3' end and / or the 5' end of the sense strand and / or the antisense strand comprises 1-5 phosphorothioate internucleotide linkages, preferably 2-3 phosphorothioate internucleotide linkages.

[0042] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0043] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and 21, and 2'-fluoro modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; and / or

[0044] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0045] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0046] (i) SCP modification at position 1 (counting from the 5' end);

[0047] (ii) 2′-fluoro modifications at positions 2, 4, 6, 8, 10, 12, 14, 16, and 18 (counting from the 5′ end);

[0048] (iii) 2'-O-methyl modifications at positions 3, 5, 7, 9, 11, 13, 15, 17, 19, 20 and 21 (counting from the 5' end); and / or

[0049] (iv) (counting from the 5' end) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21.

[0050] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0051] (i) 2'-deoxy modifications at positions 2, 5, 7, and 12 (counting from the 5' end);

[0052] (ii) SCP modification at position 1 (counting from the 5' end);

[0053] (iii) a 2'-fluoro modification at position 14 (counting from the 5' end);

[0054] (iv) 2'-O-methyl modifications at positions 3, 4, 6, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20 and 21 (counting from the 5' end); and / or

[0055] (v) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0056] In some embodiments, the sense strand has a length of 19 nucleotides and has:

[0057] (i) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19 (counting from the 5' end), and 2'-fluoro modified nucleotides at positions 7-9; and / or

[0058] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, and between nucleotide positions 18 and 19 (counting from the 5′ end).

[0059] In some embodiments, the sense strand has a length of 19 nucleotides and has:

[0060] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19, and 2'-fluoro modified nucleotides at positions 7-9; and / or

[0061] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 17 and 18, and between nucleotide positions 18 and 19 (counting from the 5' end).

[0062] In some embodiments, the siRNA comprises any antisense strand sequence selected from Table 5. In other embodiments, the siRNA comprises any sense strand sequence selected from Table 4. In some embodiments, the siRNA comprises any paired sense and antisense strand sequences shown in Table 6.

[0063] In some embodiments, the antisense strand is selected from any one of the modified nucleotide sequences shown in SEQ ID NOs: 100-122. In some embodiments, the sense strand is selected from any one of the modified nucleotide sequences shown in SEQ ID NOs: 80-98.

[0064] In some preferred embodiments, the dsRNA comprises any one of the following paired modified sense strand sequences and modified antisense strand sequences:

[0065] Sense strand: SEQ ID NO: 80, antisense strand: SEQ ID NO: 100;

[0066] Sense strand: SEQ ID NO: 81, antisense strand: SEQ ID NO: 101;

[0067] Sense strand: SEQ ID NO: 82, antisense strand: SEQ ID NO: 102;

[0068] Sense strand: SEQ ID NO: 83, antisense strand: SEQ ID NO: 103;

[0069] Sense strand: SEQ ID NO: 84, antisense strand: SEQ ID NO: 104;

[0070] Sense strand: SEQ ID NO: 85, antisense strand: SEQ ID NO: 105;

[0071] Sense strand: SEQ ID NO: 86, antisense strand: SEQ ID NO: 106;

[0072] Sense strand: SEQ ID NO: 87, antisense strand: SEQ ID NO: 107;

[0073] Sense strand: SEQ ID NO: 88, antisense strand: SEQ ID NO: 108;

[0074] Sense strand: SEQ ID NO: 89, antisense strand: SEQ ID NO: 109;

[0075] Sense strand: SEQ ID NO: 90, antisense strand: SEQ ID NO: 110;

[0076] Sense strand: SEQ ID NO: 91, antisense strand: SEQ ID NO: 111;

[0077] Sense strand: SEQ ID NO: 92, antisense strand: SEQ ID NO: 112;

[0078] Sense strand: SEQ ID NO: 93, antisense strand: SEQ ID NO: 113;

[0079] Sense strand: SEQ ID NO: 94, antisense strand: SEQ ID NO: 114;

[0080] Sense strand: SEQ ID NO: 95, antisense strand: SEQ ID NO: 115;

[0081] Sense strand: SEQ ID NO: 96, antisense strand: SEQ ID NO: 116;

[0082] Sense strand: SEQ ID NO: 97, antisense strand: SEQ ID NO: 117; and

[0083] Sense strand: SEQ ID NO: 98, antisense strand: SEQ ID NO: 118.

[0084] In some embodiments, the dsRNA is further conjugated to a ligand moiety comprising N-acetylgalactosamine, preferably the sense strand is conjugated to the ligand moiety, and further preferably the 3' end of the sense strand is conjugated to the ligand moiety.

[0085] In some embodiments, the ligand targets the asialoglycoprotein receptor (ASGPR).

[0086] In some embodiments, the ligand is GL6, which has the following structure:

[0087] in It indicates the position linked to the sense strand (preferably the 3' end of the sense strand) of the dsRNA via a phosphate group or a phosphorothioate group.

[0088] In some embodiments, the antisense strand comprises any one modified nucleotide sequence selected from SEQ ID NOs: 100-122. In some embodiments, the sense strand comprises any one modified nucleotide sequence selected from SEQ ID NOs: 60-78.

[0089] In some embodiments, the dsRNA comprises any one of the following paired modified sense strand sequences and modified antisense strand sequences:

[0090] Sense strand: SEQ ID NO: 60, antisense strand: SEQ ID NO: 100;

[0091] Sense strand: SEQ ID NO: 61, antisense strand: SEQ ID NO: 101;

[0092] Sense strand: SEQ ID NO: 62, antisense strand: SEQ ID NO: 102;

[0093] Sense strand: SEQ ID NO: 63, antisense strand: SEQ ID NO: 103;

[0094] Sense strand: SEQ ID NO: 64, antisense strand: SEQ ID NO: 104;

[0095] Sense strand: SEQ ID NO: 65, antisense strand: SEQ ID NO: 105;

[0096] Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 106;

[0097] Sense strand: SEQ ID NO: 67, antisense strand: SEQ ID NO: 107;

[0098] Sense strand: SEQ ID NO: 68, antisense strand: SEQ ID NO: 108;

[0099] Sense strand: SEQ ID NO: 69, antisense strand: SEQ ID NO: 109;

[0100] Sense strand: SEQ ID NO: 70, antisense strand: SEQ ID NO: 110;

[0101] Sense strand: SEQ ID NO: 71, antisense strand: SEQ ID NO: 111;

[0102] Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 112;

[0103] Sense strand: SEQ ID NO: 73, antisense strand: SEQ ID NO: 113;

[0104] Sense strand: SEQ ID NO: 74, antisense strand: SEQ ID NO: 114;

[0105] Sense strand: SEQ ID NO: 75, antisense strand: SEQ ID NO: 115;

[0106] Sense strand: SEQ ID NO: 76, antisense strand: SEQ ID NO: 116;

[0107] Sense strand: SEQ ID NO: 77, antisense strand: SEQ ID NO: 117;

[0108] Sense strand: SEQ ID NO: 78, antisense strand: SEQ ID NO: 118;

[0109] Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 119;

[0110] Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 120;

[0111] Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 121; and

[0112] Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 122.

[0113] In another aspect, the invention provides a cell comprising a dsRNA of the invention.

[0114] In another aspect, the invention provides a pharmaceutical composition comprising the dsRNA of the invention or the cell of the invention, and optionally a pharmaceutically acceptable carrier or excipient.

[0115] In another aspect, the invention provides a kit comprising a dsRNA of the invention, a cell of the invention, or a pharmaceutical composition of the invention.

[0116] In another aspect, the present invention provides a method of treating a disease or condition that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a subject, the method comprising the step of administering to the subject a dsRNA of the invention, a cell of the invention, or a pharmaceutical composition of the invention.

[0117] In another aspect, the invention provides a method of preventing at least one symptom in a subject having a disease or disorder that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2), the method comprising the step of administering to the subject a dsRNA of the invention, a cell of the invention, or a pharmaceutical composition of the invention.

[0118] In some embodiments, the disease or disorder that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2) is a MASP2-mediated or MASP2-associated disease.

[0119] In some embodiments, the MASP2-mediated or MASP2-associated disease is selected from arthritis, IgA nephropathy, thrombotic microangiopathy, venous embolism, diabetic nephropathy, and membranous nephropathy.

[0120] In another aspect, the invention provides a method of reducing the level of mannan-binding lectin-associated serine protease 2 (MASP2) in a subject, the method comprising the step of administering to the subject a dsRNA of the invention, a cell of the invention, or a pharmaceutical composition of the invention.

[0121] Detailed Description of the Invention

[0122] The following describes the embodiments of the present invention through specific examples. Those skilled in the art will readily understand the other advantages and benefits of the present invention from the disclosure herein. The present invention may also be implemented or applied through various other specific embodiments, and the details in this specification may be modified or altered based on different perspectives and applications without departing from the spirit of the present invention.

[0123] It should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing specific embodiments rather than for limiting the scope of protection of the present invention.

[0124] Throughout the specification and claims of the present invention, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0125] When the embodiment provides a numerical range, it should be understood that, unless otherwise specified in the present invention, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the examples, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any method, equipment, and material of the prior art similar or equivalent to the methods, equipment, and materials described in the examples of the present invention can also be used to realize the present invention, and all belong to the protection scope of the present invention. The following describes embodiments of the present invention in more detail.

[0126] definition

[0127] "Double-stranded region" herein refers to a region comprising two nucleic acid strands that are antiparallel and complementary or substantially complementary.

[0128] As used herein, the term "double-stranded RNA" or "dsRNA" refers to a ribonucleic acid molecule or a ribonucleic acid molecule complex comprising a double-stranded region as defined above. The two parts forming the double-stranded region can be two different parts of a larger RNA molecule, or they can be separate RNA molecules.

[0129] When the two parts are separate RNA molecules, the dsRNA herein is referred to as small interfering RNA (siRNA) or short interfering RNA (siRNA).

[0130] When the two moieties are two distinct parts of a larger molecule, that is, when the 3' end of one moiety is linked to the 5' end of the other moiety by one or more uninterrupted nucleotides in between to form a double-stranded region, the uninterrupted nucleotides used to connect the two moieties are called a "hairpin." When the two moieties are covalently linked to form a double-stranded region by a method other than a hairpin, the connection structure is called a "linker." When such dsRNA is introduced into cells, it is cleaved into siRNA by an intracellular endoribonuclease called Dicer.

[0131] The term "siRNA" herein refers to a class of double-stranded RNA molecules comprising a sense strand and an antisense strand that can mediate the silencing of a target RNA (e.g., mRNA, e.g., a transcript of a gene encoding a protein) that is complementary or substantially complementary to the antisense strand. siRNA is typically double-stranded, comprising an antisense strand that is complementary to the target RNA, and a sense strand that is complementary or substantially complementary to the antisense strand. For convenience, such mRNA is also referred to herein as mRNA to be silenced. Such a gene is also referred to as a target gene. Typically, the RNA to be silenced is an endogenous gene or a pathogen gene. In addition, RNA (e.g., tRNA) and viral RNA other than mRNA can also be targeted.

[0132] As used herein, the term "antisense strand" refers to the strand of a siRNA that contains a region that is fully complementary or substantially complementary to a target sequence.

[0133] As used herein, the term "complementary region" refers to a region on the antisense strand that is completely or substantially complementary to the target mRNA sequence. In the case where the complementary region is not completely complementary to the target sequence, mispairing can be located in the interior or terminal regions of the molecule. Typically, the most tolerated mispairing is located in the terminal regions, for example, within 5, 4, 3, 2 or 1 nucleotides at 5' and / or 3' ends. The antisense strand portion that is most sensitive to mispairing is referred to as a "seed region." For example, in a siRNA comprising a 19nt chain, the 19th position (from 5' to 3') can tolerate some mispairing.

[0134] As used herein, the term "complementary" refers to the ability of a first polynucleotide to hybridize to a second polynucleotide under certain conditions, such as stringent conditions. For example, stringent conditions may include 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA at 50° C. or 70° C. for 12-16 hours.

[0135] As used herein, "complementary" sequences, insofar as they meet the above requirements for their ability to hybridize, may also include or be formed entirely from non-Watson-Crick base pairs and / or base pairs formed from non-natural and modified nucleotides. Such non-Watson-Crick base pairs include, but are not limited to, G:U wobble base pairing or Hoogstein base pairing.

[0136] As used herein, a polynucleotide that is "at least partially complementary" or "substantially complementary" to a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of an mRNA of interest (e.g., an mRNA encoding MASP2). For example, a polynucleotide is complementary to at least a portion of a MASP2 mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding MASP2.

[0137] As used herein, the terms "complementary," "fully complementary," and "substantially complementary" can be used with respect to base pairing between the sense and antisense strands of an siRNA, or between the antisense strand of an siRNA and a target sequence.

[0138] As used herein, the term "sense strand" refers to the strand of an siRNA that includes a region that is substantially complementary to a region defined herein as the antisense strand.

[0139] A "nucleoside" is a compound composed of a purine or pyrimidine base and ribose or deoxyribose; a "nucleotide" is a compound composed of a purine or pyrimidine base, ribose or deoxyribose, and phosphate; an "oligonucleotide" is a nucleic acid molecule (RNA or DNA) having, for example, fewer than 100, 200, 300, or 400 nucleotides in length.

[0140] "Bases" are the fundamental building blocks of nucleosides, nucleotides, and nucleic acids. They contain nitrogen and are also called "nitrogenous bases." Unless otherwise specified, the capital letters A, U, T, G, and C represent the bases of nucleotides, representing adenine, uracil, thymine, guanine, and cytosine, respectively.

[0141] As used herein, the term "nucleotide overhang" refers to at least one unpaired nucleotide that protrudes from the double-stranded region of an siRNA. For example, when the 3'-end of a chain of an siRNA extends beyond the 5'-end of another chain or vice versa, there is a nucleotide overhang. The siRNA can comprise an overhang with at least one nucleotide, an overhang with at least two nucleotides, an overhang with at least three nucleotides, an overhang with at least four nucleotides, an overhang with at least five nucleotides or more. The nucleotide overhang can comprise or consist of nucleotides / modified nucleotides (including deoxynucleotides / nucleosides). One or more overhangs can be on a sense strand or an antisense strand or any combination thereof. An overhang with one or more nucleotides can be present on the 5'-end, the 3'-end or both ends of the antisense or sense strand of the siRNA.

[0142] "Blunt end" or "blunt end" or "blunt end" means that there are no unpaired nucleotides at that end of the double-stranded siRNA, i.e., no nucleotide overhangs. A "blunt-ended siRNA" is a siRNA that is double-stranded throughout the entire length of the siRNA, i.e., there are no nucleotide overhangs at either end of the molecule.

[0143] Substantially all of the nucleotides of the siRNA of the present invention are modified. For example, substantially all of the nucleotides of the sense strand are modified nucleotides, or substantially all of the nucleotides of the antisense strand are modified nucleotides, or substantially all of the nucleotides of both the sense strand and the antisense strand are modified nucleotides. In other embodiments of the present invention, all of the nucleotides of the siRNA of the present invention are modified nucleotides. For example, all of the nucleotides of the sense strand are modified nucleotides, or all of the nucleotides of the antisense strand are modified nucleotides, or all of the nucleotides of both the sense strand and the antisense strand are modified nucleotides. As used herein, "substantially all of the nucleotides are modified" means that most of the nucleotides of the siRNA of the present invention are modified, but not all of the nucleotides are modified, and may include no more than 5, 4, 3, 2 or 1 unmodified nucleotides.

[0144] As used herein, "modified nucleotides" include, but are not limited to, 2'-O-alkyl modified nucleotides (e.g., 2'-O-methyl modified nucleotides, 2'-methoxyethyl modified nucleotides), 2'-fluoro modified nucleotides, 2'-deoxy-modified nucleotides, inosine ribonucleotides, abasic nucleotides, inverted abasic deoxyribonucleotides, nucleotides containing a phosphorothioate group, vinyl phosphate modified nucleotides, locked nucleotides, unlocked nucleotides, 2'-amino-modified nucleotides, 2'-C-alkyl-modified nucleotides, 2'-O-allyl modified nucleotides, morphine-modified nucleotides, 2'-O-alkyl modified nucleotides, 2'-O-methyl ... Linonucleotides, phosphoramidates, nucleotides containing non-natural bases, terminal nucleotides attached to a cholesterol derivative or a dodecanoic acid didecylamide group, deoxyribonucleotides, 3'-terminal deoxythymine (dT) nucleotides, conformationally restricted nucleotides, restricted ethyl nucleotides, 2'-hydroxyl modified nucleotides, nucleotides containing a methylphosphonic acid group, nucleotides containing a 5'-phosphate, nucleotides containing a 5'-phosphate mimetic, diol-modified nucleotides (GNA), SCP-modified nucleotides, and 2-O-(N-methylacetamide) modified nucleotides, etc.

[0145] For example, a "2'-fluoro modified nucleotide" refers to a nucleotide in which the hydroxyl group at the 2' position of the ribose group is replaced by fluorine. A "2'-O-methyl modified nucleotide" refers to a nucleotide in which the 2'-hydroxyl group at the ribose group is replaced by a methoxy group.

[0146] A "phosphorothioate-containing nucleotide" refers to a nucleotide in which one or more oxygen atoms on the phosphate group of the nucleotide are replaced by a sulfur atom. A "phosphorothioate internucleotide linkage modification" refers to a modification in which two adjacent nucleotides are linked by a phosphorothioate.

[0147] In some embodiments, the sense strand of the siRNA of the present disclosure has modifications of at least two phosphorothioate internucleotide linkages located at positions 1 to 5 (counting from the 5' end) and / or has modifications of at least two phosphorothioate internucleotide linkages located at positions 1 to 5 (counting from the 3' end), and / or the antisense strand of the siRNA of the present disclosure has modifications of at least two phosphorothioate internucleotide linkages located at positions 1 to 5 (counting from the 5' end) and / or has modifications of at least two phosphorothioate internucleotide linkages located at positions 1 to 5 (counting from the 3' end).

[0148] As used herein, "ligand moiety" refers to a chemical moiety conjugated to an siRNA that is capable of altering the distribution, targeting, or lifespan of the siRNA. In some embodiments, the ligand moiety provides enhanced affinity for a selected target (e.g., a molecule, cell or cell type, compartment (e.g., a cell or organ compartment, tissue, organ, or region of the body) compared to, for example, an siRNA without this ligand moiety. In some embodiments, the ligand moiety targets the asialoglycoprotein receptor (ASGPR) on hepatocytes. The binding of the ligand moiety to the ASGPR mediates internalization via clathrin-coated vesicles. Endosome maturation results in a decrease in lysosomal pH, which promotes the dissociation of the ligand-receptor complex, thereby releasing the siRNA. Conjugation of the ligand moiety targeting the asialoglycoprotein receptor (ASGPR) on hepatocytes results in increased efficacy and stability of the siRNA in vivo or within a cell. This facilitates subcutaneous administration of the siRNA.

[0149] As used herein, the term "inhibit" is used interchangeably with "reduce," "silence," "downregulate," and other similar terms and includes any level of inhibition.

[0150] The phrase "inhibiting the expression of mannan-binding lectin-associated serine protease 2 (MASP2)" refers to inhibiting the expression of any MASP2 gene, as well as variants or mutants of the MASP2 gene. Thus, the MASP2 gene can be a wild-type MASP2 gene, a mutant MASP2 gene, or, in the case of a genetically manipulated cell, cell group, or organism, a transgenic MASP2 gene.

[0151] "Inhibiting the expression of the MASP2 gene" includes any level of inhibition of the MASP2 gene, such as at least partial inhibition of MASP2 gene expression. MASP2 gene expression can be assessed based on the level or change in the level of any variable associated with MASP2 gene expression, such as MASP2 mRNA level, MASP2 protein level. This level can be assessed in a single cell or in a group of cells (including, for example, a sample derived from a subject).

[0152] Inhibition can be assessed by a decrease in the absolute or relative level of one or more variables associated with MASP2 expression compared to a control level. The control level can be any type of control level utilized in the art, such as a pre-dose baseline level or a level determined from a similar untreated or control (e.g., a buffer-only control or an inert agent control) treated subject, cell, or sample.

[0153] "Hydroxy protecting group" refers to a group that can prevent the hydroxyl group from chemical reaction and can be removed under specific conditions to restore the hydroxyl group. It mainly includes silane type protecting groups, acyl type protecting groups or ether type protecting groups, preferably the following: trimethylsilyl (TMS), triethylsilyl (TES), dimethylisopropylsilyl (DMIPS), diethylisopropylsilyl (DEIPS), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), triisopropylsilyl (TIPS), acetyl (Ac), chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl (TFA), benzoyl, p-methoxybenzoyl, 9-fluorenylmethoxycarbonyl ( Fmoc), allyloxycarbonyl (Alloc), 2,2,2-trichloroethoxycarbonyl (Troc), benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), benzyl (Bn), p-methoxybenzyl (PMB), allyl, triphenylmethyl (Tr), bis-p-methoxytrityl (DMTr), methoxymethyl (MOM), phenoxymethyl (BOM), 2,2,2-trichloroethoxymethyl, 2-methoxyethoxymethyl (MEM), methylthiomethyl (MTM), p-methoxybenzyloxymethyl (PMBM).

[0154] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0155] “C 1-6 "Haloalkyl" refers to the above-mentioned "C 1-6 Alkyl", which is substituted by one or more halogen groups. In some embodiments, C 1-4 Halogenated alkyl is particularly preferred, more preferably C 1-2 Haloalkyl. Exemplary haloalkyl groups include, but are not limited to, -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2,2,2-trifluoro-1,1-dimethyl-ethyl, and the like. The haloalkyl group can be substituted at any available point of attachment, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0156] “C 1-6 "Alkylene" refers to the removal of C 1-6 In some embodiments, C 1-4 Alkylene, C 2-4 Alkylene and C 1-2Alkylene is preferred. Unsubstituted alkylene includes, but is not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylenes, for example, alkylenes substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted methylene (-CH(CH3)-, -C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3) 2- ), substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), and the like.

[0157] As used herein, the terms "treat", "treat", and the like refer to the administration of an agent or the performance of a procedure in order to obtain an effect. These effects may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of affecting a partial or complete cure of a disease and / or disease symptoms. As used herein, "treatment" may include the treatment of a disease or condition (e.g., cancer) in a mammal, particularly a human, and includes: (a) preventing the occurrence of the disease or disease symptoms in a subject susceptible to the disease but not yet diagnosed as having the disease (e.g., including diseases that may be associated with or caused by the primary disease); (b) inhibiting the disease, i.e., preventing its development; (c) alleviating the disease, i.e., causing regression of the disease. Treatment may refer to any reference to success in treating, ameliorating, or preventing cancer, including any objective or subjective parameter, such as elimination; alleviation; reducing symptoms or making the disease condition more tolerable for the patient; slowing the rate of deterioration or decline; or reducing the end point of deterioration. Treatment or improvement of symptoms is based on one or more objective or subjective parameters; including the results of a doctor's examination. Thus, the term "treatment" includes administering an antibody, composition, or conjugate disclosed herein to prevent, delay, alleviate, arrest, or inhibit the development of symptoms or conditions associated with a disease (e.g., cancer). The term "therapeutic effect" refers to the reduction, elimination, or prevention of a disease, disease symptom, or disease side effect in a subject.

[0158] The term "effective amount" as used herein refers to an amount that, when administered to a subject for treating a disease, is sufficient to effect such treatment.

[0159] As used herein, the term "subject" refers to any mammalian subject for whom diagnosis, treatment, or therapy is desired. "Mammal" for therapeutic purposes refers to any animal classified as a mammal, including humans, livestock, and laboratory, zoo, sport, or pet animals, such as dogs, horses, cats, cows, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, monkeys, and the like.

[0160] I.dsRNA

[0161] The present invention provides a double-stranded nucleic acid (dsRNA) for inhibiting the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a cell, wherein the dsRNA comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand and the antisense strand are each independently 15-30 nucleotides in length, and the antisense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 22-40.

[0162] In some embodiments, the double-stranded region formed by the sense strand and the antisense strand is fully complementary. In other embodiments, the double-stranded region formed by the sense strand and the antisense strand is substantially complementary and may comprise 1, 2, 3, 4 or 5 non-complementary sites.

[0163] In some specific embodiments, the sense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 2-20.

[0164] In some embodiments, the sense strand and the antisense strand are each independently 17-27 nucleotides in length, preferably 18-25 nucleotides, and more preferably 19-21 nucleotides in length.

[0165] In some embodiments, the length of the double-stranded region is 15-25 nucleotide pairs, preferably 16-23 nucleotide pairs, and more preferably 18-20 nucleotide pairs.

[0166] In some embodiments, the dsRNA of the present invention is siRNA.In other embodiments, a hairpin loop is formed between the sense strand and the antisense strand of the dsRNA of the present invention.

[0167] One or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having at least one nucleotide, for example, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having at least one nucleotide. In some preferred embodiments, the antisense strand has a 3' overhang and / or a 5' overhang having at least two nucleotides, preferably, the antisense strand comprises a 3' overhang and / or a 5' overhang having two nucleotides. In some embodiments, the sense strand and the antisense strand are the same length. In some embodiments, the full length of the sense strand is complementary to the full length of the antisense strand to form a double strand, i.e., it has a blunt end. In other embodiments, the sense strand and the antisense strand are the same length, a portion of the sense strand is complementary to a portion of the antisense strand, i.e., both the sense strand and the antisense strand have a 5' overhang. In some embodiments, the sense strand and the antisense strand are different in length. In a preferred embodiment, the 5' end of the antisense strand has an overhang of at least one nucleotide, more preferably an overhang of two or three nucleotides.

[0168] The dsRNA of the present invention is included in a dsRNA having a nucleotide overhang (that is, a reagent with an overhang and a blunt end) at one end or at both ends. For example, the 5'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the sense strand comprises an overhang with one or more nucleotides. For example, the 5'-end of the antisense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 5'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 5'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 3'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 5'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 5'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 3'-end of the sense strand of the dsRNA comprises an overhang having one or more nucleotides and the 3'-end of the sense strand comprises a blunt end. For example, the 5'-end of the antisense strand of the dsRNA comprises an overhang having one or more nucleotides and the 3'-end of the antisense strand comprises a blunt end. For example, the 3'-end of the antisense strand of the dsRNA comprises an overhang having one or more nucleotides and the 5'-end of the antisense strand comprises a blunt end.

[0169] In some embodiments, the antisense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, a nucleotide sequence of at least 18 consecutive nucleotides, a nucleotide sequence of at least 19 consecutive nucleotides, or a nucleotide sequence of at least 20 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 22-40. Preferably, the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 22-40.

[0170] In some embodiments, the sense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, or a nucleotide sequence of at least 18 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 2-20, and preferably the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 2-20.

[0171] In some embodiments, the siRNA comprises any one of the following paired sense and antisense sequences:

[0172] (1) Sense strand: SEQ ID NO: 2, antisense strand: SEQ ID NO: 22;

[0173] (2) Sense strand: SEQ ID NO: 3, antisense strand: SEQ ID NO: 23;

[0174] (3) Sense strand: SEQ ID NO: 4, antisense strand: SEQ ID NO: 24;

[0175] (4) Sense strand: SEQ ID NO: 5, antisense strand: SEQ ID NO: 25;

[0176] (5) Sense strand: SEQ ID NO: 6, antisense strand: SEQ ID NO: 26;

[0177] (6) Sense strand: SEQ ID NO: 7, antisense strand: SEQ ID NO: 27;

[0178] (7) Sense strand: SEQ ID NO: 8, antisense strand: SEQ ID NO: 28;

[0179] (8) Sense strand: SEQ ID NO: 9, antisense strand: SEQ ID NO: 29;

[0180] (9) Sense strand: SEQ ID NO: 10, antisense strand: SEQ ID NO: 30;

[0181] (10) Sense strand: SEQ ID NO: 11, antisense strand: SEQ ID NO: 31;

[0182] (11) Sense strand: SEQ ID NO: 12, antisense strand: SEQ ID NO: 32;

[0183] (12) Sense strand: SEQ ID NO: 13, antisense strand: SEQ ID NO: 33;

[0184] (13) Sense strand: SEQ ID NO: 14, antisense strand: SEQ ID NO: 34;

[0185] (14) Sense strand: SEQ ID NO: 15, antisense strand: SEQ ID NO: 35;

[0186] (15) Sense strand: SEQ ID NO: 16, antisense strand: SEQ ID NO: 36;

[0187] (16) Sense strand: SEQ ID NO: 17, antisense strand: SEQ ID NO: 37;

[0188] (17) Sense strand: SEQ ID NO: 18, antisense strand: SEQ ID NO: 38;

[0189] (18) sense strand: SEQ ID NO: 19, antisense strand: SEQ ID NO: 39; and

[0190] (19) Sense strand: SEQ ID NO: 20, antisense strand: SEQ ID NO: 40.

[0191] II. Modification of Nucleotides

[0192] In some embodiments, substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides. In some embodiments, at least 80% of the nucleotides of the sense strand are modified nucleotides, and / or at least 80%, at least 85%, at least 90%, at least 92%, at least 95% of the nucleotides of the antisense strand are modified nucleotides. In some embodiments, at least 80% of the nucleotides of the antisense strand are modified nucleotides, and / or at least 80%, at least 85%, at least 90%, at least 92%, at least 95% of the nucleotides of the antisense strand are modified nucleotides. In some embodiments, at least 80% of the nucleotides of the sense strand are modified nucleotides, and / or at least 80%, at least 85%, at least 90%, at least 92%, at least 95% of the nucleotides of the antisense strand are modified nucleotides, and at least 80% of the nucleotides of the antisense strand are modified nucleotides, and / or at least 80%, at least 85%, at least 90%, at least 92%, at least 95% of the nucleotides of the antisense strand are modified nucleotides.

[0193] In some embodiments, all nucleotides of the sense strand are modified nucleotides and / or all nucleotides of the antisense strand are modified nucleotides.

[0194] The modification of the nucleotides described in the present invention may be modification of the phosphate group, ribose group and / or base group of the nucleotides.

[0195] In some specific embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of 2'-O-alkyl modified nucleotides (e.g., 2'-O-methyl modified nucleotides, 2'-methoxyethyl modified nucleotides), 2'-fluoro modified nucleotides, 2'-deoxy-modified nucleotides, inosine ribonucleotides, abasic nucleotides, inverted abasic deoxyribonucleotides, nucleotides containing thiophosphate groups, vinyl phosphate modified nucleotides, locked nucleotides, unlocked nucleotides, 2'-amino-modified nucleotides, 2'-C-alkyl-modified nucleotides, 2'-O-allyl modified nucleotides, morpholino nucleotides, phosphoramidates, nucleotides containing non-natural bases, terminal nucleotides attached to a cholesteryl derivative or a dodecyldiamide group, deoxyribonucleotides, 3'-terminal deoxythymidine (dT) nucleotides, conformationally restricted nucleotides, restricted ethyl nucleotides, 2'-hydroxyl modified nucleotides, nucleotides containing a methylphosphonic acid group, nucleotides containing a 5'-phosphate, nucleotides containing a 5'-phosphate mimetic, diol-modified nucleotides (GNA), and 2-O-(N-methylacetamide) modified nucleotides.

[0196] In some preferred embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, SCP modified nucleotides, and phosphorothioate internucleotide linkage modifications.

[0197] In some preferred embodiments, the sense strand and / or antisense strand comprises at least 2 2'-fluoro-modified nucleotides. In some preferred embodiments, the sense strand and / or antisense strand comprises at least 8 2'-O-methyl-modified nucleotides. In some preferred embodiments, the 3' end and / or 5' end of the sense strand and / or antisense strand comprises 1-5 phosphorothioate groups, preferably 2-3 phosphorothioate groups. In some preferred embodiments, the sense strand and / or antisense strand comprises adenine deoxyribonucleotides, thymine deoxyribonucleotides, guanine deoxyribonucleotides and / or cytosine deoxyribonucleotides. In a more preferred embodiment, the sense strand and / or antisense strand comprises thymine deoxyribonucleotides. In a most preferred embodiment, the sense strand comprises thymine deoxyribonucleotides.

[0198] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0199] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and 21, and 2'-fluoro modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; and / or

[0200] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0201] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0202] (i) SCP modification at position 1 (counting from the 5' end);

[0203] (ii) 2′-fluoro modifications at positions 2, 4, 6, 8, 10, 12, 14, 16, and 18 (counting from the 5′ end);

[0204] (iii) 2'-O-methyl modifications at positions 3, 5, 7, 9, 11, 13, 15, 17, 19, 20 and 21 (counting from the 5' end); and / or

[0205] (iv) (counting from the 5' end) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21.

[0206] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0207] (i) 2'-deoxy modifications at positions 2, 5, 7, and 12 (counting from the 5' end);

[0208] (ii) SCP modification at position 1 (counting from the 5' end);

[0209] (iii) a 2'-fluoro modification at position 14 (counting from the 5' end);

[0210] (iv) 2'-O-methyl modifications at positions 3, 4, 6, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20 and 21 (counting from the 5' end); and / or

[0211] (v) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0212] In some embodiments, the sense strand has a length of 19 nucleotides and has:

[0213] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19, and 2'-fluoro modified nucleotides at positions 7-9; and / or

[0214] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, and between nucleotide positions 18 and 19 (counting from the 5′ end).

[0215] In some embodiments, the sense strand has a length of 19 nucleotides and has:

[0216] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19, and 2'-fluoro modified nucleotides at positions 7-9; and / or

[0217] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 17 and 18, and between nucleotide positions 18 and 19 (counting from the 5' end).

[0218] In some embodiments, the siRNA comprises any antisense strand sequence selected from Table 5. In other embodiments, the siRNA comprises any sense strand sequence selected from Table 4. In some embodiments, the siRNA comprises any paired sense and antisense strand sequences shown in Table 6.

[0219] III. Ligand

[0220] The dsRNA of the present invention is further conjugated to a ligand moiety comprising N-acetylgalactosamine. In preferred embodiments, the sense strand of the dsRNA is conjugated to the ligand moiety. In some preferred embodiments, the 3' end of the sense strand is conjugated to the ligand moiety. In other preferred embodiments, the 5' end of the sense strand is conjugated to the ligand moiety.

[0221] In some embodiments, the ligand moiety comprises a conjugate group represented by formula (X'):

[0222] in,

[0223] Indicates the position of attachment to dsRNA;

[0224] Q is independently H,

[0225] Wherein L1 is a chemical bond, -CH2-, -CH2CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0226] L2 is a chemical bond or -CH2CH2C(O)-;

[0227] L3 is a chemical bond, -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0228] L4 is -(OCH2CH2) c -、-(OCH2CH2CH2) c -、-(OCH2CH2CH2CH2) c -、-(OCH2CH2CH2CH2CH2) c -or-NHC(O)-(CH2) d -;

[0229] Where a = 0, 1, 2 or 3;

[0230] b = 1, 2, 3, 4, or 5;

[0231] c = 1, 2, 3, 4, or 5;

[0232] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0233] L is a chemical bond, -CH2O- or -NHC(O)-;

[0234] L' is a chemical bond, -C(O)NH-, -NHC(O)- or -O(CH2CH2O) e -;

[0235] Where e is 1, 2, 3, 4 or 5;

[0236] T is a chemical bond, -CH2-, -C(O)-, -M-, -CH2-M- or -C(O)-M-;

[0237] Where M is

[0238] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0239] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0240] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0241] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0242] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0243] In some embodiments, the conjugated group is represented by formula (I'):

[0244] in,

[0245] Indicates the position where it is linked to the dsRNA;

[0246] Q is independently H,

[0247] Wherein L1 is a chemical bond, -CH2-, -CH2CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0248] L2 is a chemical bond or -CH2CH2C(O)-;

[0249] L3 is a chemical bond, -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0250] L4 is -(OCH2CH2) c -、-(OCH2CH2CH2) c -、-(OCH2CH2CH2CH2) c -、-(OCH2CH2CH2CH2CH2) c -or-NHC(O)-(CH2) d -;

[0251] Where a = 0, 1, 2 or 3;

[0252] b = 1, 2, 3, 4, or 5;

[0253] c = 1, 2, 3, 4, or 5;

[0254] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0255] L is -CH2O- or -NHC(O)-;

[0256] L' is a chemical bond, -C(O)NH- or -NHC(O)-;

[0257] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0258] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0259] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0260] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0261] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0262] In some specific embodiments, wherein,

[0263] Q is independently H or

[0264] Where L1 is -CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0265] L2 is -CH2CH2C(O)-;

[0266] L3 is -(NHCH2CH2) b -or-(NHCH2CH2CH2) b -;

[0267] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0268] Where a = 0, 1, 2 or 3;

[0269] b = 1, 2, 3, 4, or 5;

[0270] c = 1, 2, 3, 4, or 5;

[0271] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0272] L is -CH2O-;

[0273] L' is a chemical bond;

[0274] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0275] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0276] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0277] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0278] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0279] In some embodiments, the conjugated group is represented by Formula (I'-1), Formula (I'-2), or Formula (I'-3):

[0280] in,

[0281] Indicates the position of attachment to dsRNA;

[0282] Q is

[0283] Wherein L1 is -CH2O- or -NHC(O)-;

[0284] L2 is -CH2CH2C(O)-;

[0285] L3 is -(NHCH2CH2) b -or-(NHCH2CH2CH2) b -;

[0286] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0287] Where b = 1, 2, 3, 4 or 5;

[0288] c = 1, 2, 3, 4, or 5;

[0289] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0290] L is -CH2O-;

[0291] R' is H, a hydroxyl protecting group or a solid phase support, wherein the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0292] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0293] In some specific embodiments, wherein,

[0294] Q is independently H,

[0295] Wherein L1 is -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0296] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2)b - or -C(O)CH2-;

[0297] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0298] Where a = 0, 1, 2 or 3;

[0299] b = 1, 2, 3, 4, or 5;

[0300] c = 1, 2, 3, 4, or 5;

[0301] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0302] L is -CH2O- or -NHC(O)-;

[0303] L' is a chemical bond or -C(O)NH-;

[0304] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0305] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0306] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0307] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0308] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0309] In some embodiments, the conjugated group is as shown in Formula (II'-1) or Formula (II'-2):

[0310] in,

[0311] Indicates the position of attachment to dsRNA;

[0312] Q is independently

[0313] Wherein L1 is -CH2O- or -CH2O-CH2CH2O-;

[0314] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0315] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0316] Where b = 1, 2, 3, 4 or 5;

[0317] c = 1, 2, 3, 4, or 5;

[0318] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0319] L is -NHC(O)-;

[0320] L' is a chemical bond or -C(O)NH-;

[0321] R' is H, a hydroxyl protecting group or a solid phase support, wherein the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0322] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0323] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0324] In some specific embodiments, wherein,

[0325] Q is independently H,

[0326] Wherein L1 is -CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0327] L2 is a chemical bond;

[0328] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0329] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0330] Where a = 0, 1, 2 or 3;

[0331] b = 1, 2, 3, 4, or 5;

[0332] c = 1, 2, 3, 4, or 5;

[0333] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0334] L is -CH2O- or -NHC(O)-;

[0335] L' is a chemical bond or -C(O)NH-;

[0336] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0337] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0338] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0339] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0340] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0341] In some embodiments, the conjugated group is represented by formula (II'-2):

[0342] in,

[0343] Indicates the position of attachment to dsRNA;

[0344] Q is independently

[0345] Wherein L1 is -CH2- or -C(O)-;

[0346] L3 is -(NHCH2CH2) b -;

[0347] L4 is -(OCH2CH2) c -;

[0348] Where b = 1, 2, 3, 4 or 5;

[0349] c = 1, 2, 3, 4, or 5;

[0350] L is -CH2O- or -NHC(O)-;

[0351] R' is H, a hydroxyl protecting group or a solid phase support, wherein the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0352] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0353] In some specific embodiments, wherein:

[0354] Q is independently H,

[0355] Wherein L1 is a chemical bond, -CH2-, -CH2CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0356] L2 is a chemical bond or -CH2CH2C(O)-;

[0357] L3 is a chemical bond, -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0358] L4 is -(OCH2CH2) c -、-(OCH2CH2CH2) c -、-(OCH2CH2CH2CH2) c -、-(OCH2CH2CH2CH2CH2) c -or-NHC(O)-(CH2) d -;

[0359] Where a = 0, 1, 2 or 3;

[0360] b = 1, 2, 3, 4, or 5;

[0361] c = 1, 2, 3, 4, or 5;

[0362] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0363] L is a chemical bond, -CH2O- or -NHC(O)-;

[0364] L' is a chemical bond, -C(O)NH-, -NHC(O)- or -O(CH2CH2O) e -;

[0365] Where e is 1, 2, 3, 4 or 5;

[0366] T is a chemical bond, -CH2-, -M-, -CH2-M- or -C(O)-M-;

[0367] Where M is

[0368] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0369] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0370] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0371] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0372] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0373] In some specific embodiments, wherein,

[0374] T is -M-, -CH2-M- or -C(O)-M-, wherein M is

[0375] In some specific embodiments, wherein,

[0376] Q is independently H or

[0377] Where L1 is -CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0378] L2 is -CH2CH2C(O)-;

[0379] L3 is -(NHCH2CH2) b -or-(NHCH2CH2CH2) b -;

[0380] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0381] Where a = 0, 1, 2 or 3;

[0382] b = 1, 2, 3, 4, or 5;

[0383] c = 1, 2, 3, 4, or 5;

[0384] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0385] L is a chemical bond or -CH2O-;

[0386] L' is a chemical bond or -O(CH2CH2O) e -;

[0387] Where e is 1, 2, 3, 4 or 5;

[0388] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0389] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0390] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0391] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0392] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0393] wherein T is as defined in the above embodiment.

[0394] In some embodiments, the conjugated group is represented by Formula (III'-1), Formula (III'-2), or Formula (III'-3):

[0395] in,

[0396] Q is

[0397] Wherein L1 is -CH2O- or -NHC(O)-;

[0398] L2 is -CH2CH2C(O)-;

[0399] L3 is -(NHCH2CH2) b -or-(NHCH2CH2CH2) b -;

[0400] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0401] Where b = 1, 2, 3, 4 or 5;

[0402] c = 1, 2, 3, 4, or 5;

[0403] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0404] L is a chemical bond or -CH2O-;

[0405] Wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0406] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0407] wherein T is as defined in the above embodiment.

[0408] In some specific embodiments, wherein,

[0409] Q is independently H,

[0410] Wherein L1 is -CH2-, -CH2O- or -C(O)-;

[0411] L2 is a chemical bond;

[0412] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0413] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0414] Where b = 1, 2, 3, 4 or 5;

[0415] c = 1, 2, 3, 4, or 5;

[0416] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0417] L is a chemical bond or -NHC(O)-;

[0418] L' is a chemical bond;

[0419] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0420] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0421] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0422] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0423] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0424] wherein T is as defined in the above embodiment.

[0425] In some embodiments, the conjugated group is represented by formula (IV-1) or formula (IV-2):

[0426] in,

[0427] Q is independently

[0428] Wherein L1 is -CH2-, -CH2O- or -C(O)-;

[0429] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0430] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0431] Where b = 1, 2, 3, 4 or 5;

[0432] c = 1, 2, 3, 4, or 5;

[0433] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0434] L is a chemical bond or -NHC(O)-;

[0435] L' is a chemical bond;

[0436] Wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0437] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0438] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0439] wherein T is as defined in the above embodiment.

[0440] In some specific embodiments, wherein:

[0441] Q is independently H,

[0442] Wherein L1 is a chemical bond, -CH2-, -CH2CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0443] L2 is a chemical bond or -CH2CH2C(O)-;

[0444] L3 is a chemical bond, -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0445] L4 is -(OCH2CH2) c -、-(OCH2CH2CH2) c -、-(OCH2CH2CH2CH2) c -、-(OCH2CH2CH2CH2CH2) c -or-NHC(O)-(CH2) d -;

[0446] Where a = 0, 1, 2 or 3;

[0447] b = 1, 2, 3, 4, or 5;

[0448] c = 1, 2, 3, 4, or 5;

[0449] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0450] L is a chemical bond, -CH2O- or -NHC(O)-;

[0451] L' is -O(CH2CH2O) e -;

[0452] Where e is 1, 2, 3, 4 or 5;

[0453] T is a chemical bond, -CH2-, -C(O)-, -M-, -CH2-M- or -C(O)-M-;

[0454] Where M is

[0455] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0456] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0457] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0458] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0459] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0460] In some preferred embodiments, the conjugated group is selected from the following Table 1:

[0461] In some preferred embodiments, the conjugated group is selected from the following Table 2:

[0462] In some embodiments, the ligand targets the asialoglycoprotein receptor (ASGPR).In some embodiments, the ligand targets the asialoglycoprotein receptor (ASGPR) on hepatocytes.

[0463] In a preferred embodiment, the ligand has the following structure:

[0464] in Indicates the position of attachment to the dsRNA via a phosphate group or a phosphorothioate group.

[0465] In a preferred embodiment, the ligand has the following structure:

[0466] in Indicates the position of attachment to the dsRNA via a phosphate group or a phosphorothioate group.

[0467] In a preferred embodiment, the ligand has the following structure:

[0468] in Indicates the position of linkage to the sense strand of the dsRNA via a phosphate group or a phosphorothioate group.

[0469] In a preferred embodiment, the ligand has the following structure:

[0470] in Indicates the position of linkage to the sense strand of the dsRNA via a phosphate group or a phosphorothioate group.

[0471] IV. Inhibition of MASP2 Gene Expression

[0472] The dsRNA of the invention is capable of inhibiting MASP2 gene expression by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0473] Inhibition of MASP2 gene expression can be manifested by a decrease in the amount of mRNA expressed by a first cell or group of cells (such cells can be present, for example, in a sample derived from a subject) in which the MASP2 gene is transcribed and which cell or cells have been treated (e.g., by contacting the cell or cells with a dsRNA of the invention, or by administering a dsRNA of the invention to a subject in which such cells are or were present) such that MASP2 gene expression is inhibited compared to a second cell or group of cells (one or more control cells) that is substantially identical to the first cell or group of cells but has not been so treated.

[0474] In preferred embodiments, inhibition is assessed by expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells using the formula: -△△Ct The difference between the experimental group and the control group was compared by ΔΔCt, where ΔΔCt = [(Ct target gene of experimental group - Ct internal reference of experimental group) - (Ct target gene of control group - Ct internal reference of control group)].

[0475] Alternatively, inhibition of MASP2 gene expression, e.g., MASP2 protein expression, can be assessed in terms of a reduction in parameters functionally related to MASP2 gene expression, such as lipid levels, cholesterol levels, e.g., LDLc levels. MASP2 gene silencing can be determined in any cell that expresses MASP2, either constitutively or through genome engineering, and by any assay known in the art. The liver is a major site of MASP2 expression, and other important sites of expression include.

[0476] Inhibition of expression of a MASP2 protein can be demonstrated by a decrease in the level of MASP2 protein expressed by a cell or cell group (e.g., the level of protein expressed in a sample derived from a subject). As explained above with respect to the assessment of mRNA inhibition, inhibition of protein expression levels in treated cells or cell groups can similarly be expressed as a percentage of the level of protein in control cells or cell groups.

[0477] Control cells or cell groups that can be used to assess inhibition of MASP2 gene expression include cells or cell groups that have not been contacted with the dsRNA of the invention. For example, the control cells or cell groups can be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with the dsRNA.

[0478] V. Cells

[0479] The present invention provides a cell comprising the dsRNA of the present invention, wherein the dsRNA of the present invention is capable of being transcribed in the cell.

[0480] VI. Pharmaceutical Compositions

[0481] The present invention provides a pharmaceutical composition comprising the dsRNA or cells of the present invention, and optionally a pharmaceutically acceptable carrier or excipient.

[0482] As used herein, "pharmaceutically acceptable" refers to those compounds, materials, compositions, and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human and animal subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0483] As used herein, a pharmaceutically acceptable carrier refers to a pharmaceutical carrier that facilitates administration of dsRNA or vectors or cells containing its coding sequence into the human body and / or facilitates its absorption or function. Examples include diluents and excipients such as water; fillers such as starch and sucrose; binders such as cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; humectants such as glycerol; disintegrants such as agar, calcium carbonate, and sodium bicarbonate; absorption enhancers such as quaternary ammonium compounds; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and bentonite; and lubricants such as talc, calcium / magnesium stearate, and polyethylene glycol. Other adjuvants such as flavoring agents and sweeteners may also be added to the composition.

[0484] For example, a pharmaceutical composition comprising the dsRNA, vector or cell of the present invention may comprise a pharmaceutically acceptable diluent or a sustained-release matrix, in which the dsRNA or vector of the present invention is embedded.

[0485] The pharmaceutical compositions of the present invention may comprise a drug delivery system for delivering dsRNA, such as nanoparticles, polymers, liposomes, PEG, or a cationic delivery system.

[0486] VII. Kit

[0487] The present invention provides a kit comprising the dsRNA, cells or pharmaceutical composition of the present invention.

[0488] The present invention also provides kits for using the dsRNAs described herein and / or performing the methods described herein. Such kits include one or more dsRNAs, cells, or pharmaceutical compositions described herein, and may further include instructions for use. The instructions may include instructions for inhibiting MASP2 expression in cells by contacting the cells with the dsRNAs described herein in an amount effective to inhibit MASP2 expression.

[0489] In cases where the dsRNA of the present invention is contacted with cells in vitro, the kits of the present invention may optionally further include means for contacting cells with the dsRNA of the present invention (e.g., an injection device) or means for measuring the inhibitory effect of MASP2 (e.g., a device for measuring the inhibition of MASP2 mRNA or protein). Such means for measuring the inhibition of MASP2 may include means for obtaining a sample (such as, for example, a plasma sample) from a subject.

[0490] When the dsRNA or pharmaceutical composition of the present invention or cells into which the dsRNA has been introduced in vitro are administered in vivo, the kit of the present invention may optionally further comprise a device for administering the dsRNA, cells or pharmaceutical composition of the present invention to a subject or a device for determining a therapeutically effective amount or a prophylactically effective amount.

[0491] VIII. Methods of treatment and pharmaceutical uses

[0492] The present invention provides a method for reducing mannan-binding lectin-associated serine protease 2 (MASP2) in a subject, comprising the step of administering to the subject the dsRNA, cell, or pharmaceutical composition of the present invention.

[0493] The present invention provides a method for treating, preventing, inhibiting, or ameliorating a disease or condition that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a subject, the method comprising administering to the subject a dsRNA, cell, or pharmaceutical composition of the present invention. The present invention also provides a method for treating, preventing, inhibiting, or ameliorating at least one symptom in a patient suffering from a disease or condition that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2).

[0494] In some embodiments, the disease or condition that benefits from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2) is a MASP2-associated disease. In some embodiments, the MASP2-associated disease is arthritis, IgA nephropathy, thrombotic microangiopathy, venous embolism, diabetic nephropathy, and membranous nephropathy.

[0495] In some embodiments, the present invention provides a method of reducing MASP2 expression in a subject, a method of treating, preventing, inhibiting, or ameliorating a disease or condition that would benefit from reduced MASP2 expression in a subject, or a method of treating, preventing, inhibiting, or ameliorating at least one symptom in a patient suffering from a disease or condition that would benefit from reduced MASP2 expression, comprising administering the dsRNA or pharmaceutical composition subcutaneously or intravenously to the subject. In some embodiments, the subject is a human patient.

[0496] The present invention also relates to the dsRNA, cells or pharmaceutical compositions of the present invention for use in treating a disease or condition associated with MASP2 expression in a subject.

[0497] The present invention also relates to the use of the dsRNA, cells, or pharmaceutical compositions of the present invention in the preparation of a medicament for treating, preventing, inhibiting, or alleviating a disease or condition that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a subject. The present invention also relates to the use of the dsRNA, cells, or pharmaceutical compositions of the present invention in the preparation of a medicament for reducing mannan-binding lectin-associated serine protease 2 (MASP2) in a subject. The present invention also relates to the use of the dsRNA, cells, or pharmaceutical compositions of the present invention in the preparation of a medicament for treating, preventing, inhibiting, or alleviating at least one symptom in a patient suffering from a disease or condition that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2). The medicament of the present invention can be prepared as an emulsion, microemulsion, microparticle, or the like.

[0498] sequence

[0499] The RNA sequences provided herein target the human MASP2 gene (or target gene, target mRNA sequence, target sequence). The target MASP2 mRNA sequence is shown in Genbank accession number NM_006610.3. The dsRNA sequences provided herein are shown in Table 3.

[0500] Table 3. Nucleotide sequences of the sense and antisense strands targeting MASP2 mRNA

[0501] Tables 4 and 5 show the modified RNA sequences used in the present invention.

[0502] In this article, the meanings of the abbreviations are as follows:

[0503] The A, U, G, and C distribution represents the natural adenine, uracil, guanine, and cytosine ribonucleotides.

[0504] d indicates that the nucleotide adjacent to its right is a deoxyribonucleotide. For example, dA, dT, dG, and dC represent adenine deoxyribonucleotide, thymine deoxyribonucleotide, guanine deoxyribonucleotide, and cytosine deoxyribonucleotide, respectively.

[0505] m indicates that the nucleotide adjacent to its left is a 2'-OCH3-modified nucleotide. For example, Am, Um, Gm, and Cm represent 2'-OCH3-modified A, U, G, and C, respectively.

[0506] f indicates that the nucleotide adjacent to its left is a 2'-fluoro-modified nucleotide. For example, Af, Uf, Gf, and Cf represent 2'-fluoro-modified A, U, G, and C, respectively.

[0507] "s" indicates that the two adjacent nucleotides on the left and right are linked by phosphorothioate.

[0508] “s-” indicates that the adjacent nucleotide on its left and the adjacent ligand on its right are linked by phosphorothioate.

[0509] "SCP1a-X" represents a modified nucleotide X having the following structure: X represents a nucleotide selected from adenine, guanine, uracil and cytosine, wherein Base is the base of the nucleotide.

[0510] "SCP modification" refers to a modified nucleotide having the following structure: Wherein Base is independently selected from H, a modified or unmodified base or a leaving group. Preferably, Base is an unmodified base selected from adenine base, guanine base, uracil base and cytosine base. In other embodiments, Base is a modified base.

[0511] VP indicates that the adjacent nucleotide on its right is a vinyl phosphate-modified nucleotide, which is well known in the art, and can be found in, for example, PCT Publication Nos. WO2011139702, WO2013033230, and WO2019105419.

[0512] L96 represents a GalNAc ligand of the following structure well known in the art, wherein Refers to positions linked to the dsRNA via a phosphate group or a phosphorothioate group, see, for example, PCT Publication Nos. WO2009073809 and WO2009082607.

[0513] GL6 represents a GalNAc ligand of the following structure, wherein Indicates the position where the dsRNA is linked via a phosphate or phosphorothioate group

[0514] Table 4. Modified siRNA sense strand sequences targeting the MASP2 gene

[0515] Table 5. Modified siRNA antisense strand sequences targeting the MASP2 gene

[0516] Table 6. Paired siRNA sense and antisense strands targeting the MASP2 gene

[0517] The present invention will be further described below with reference to the following examples. It should be understood that the following examples are merely illustrative and should not be considered as limiting the scope of the present invention. Example

[0518] Unless otherwise specified, the sources of materials used in the examples are as follows:

[0519] Huh7 cell line was purchased from Nanjing Kebai, catalog number CBP60202;

[0520] Hep3B cell line was purchased from Nanjing Kebai, catalog number CBP60197;

[0521] PHH cells were purchased from Shanghai Xuanyi, catalog number QYLF-HPMC;

[0522] PMH cells were purchased from Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd., catalog number 110872;

[0523] HEK293A cell line was purchased from Nanjing Kebai, catalog number CBP60436;

[0524] Balb / c mice were obtained from Zhejiang Weitonglihua, catalog number Balb / c.

[0525] Example 1 Preparation of Compound E7

[0526] 1. Preparation of Intermediates 3-4

[0527] 1.1 Preparation of Compound 2

[0528] To compound 1 (300 g, 2.01 mol) in DCM (1.80 L) was slowly added benzyl (2,5-dioxopyrrolidin-1-yl) carbonate (600 g, 2.40 mol) at 15°C and TEA (203 g, 2.01 mol, 280 mL) was added dropwise. After the addition, the mixture was stirred at 25°C for 16 hours. TLC (dichloromethane:methanol=10:1) showed that reactant 1 (R f =0.32) is retained and an important new point is detected (R f =0.52). The reaction mixture was washed with saturated sodium bicarbonate solution (1.00 L x 2), and the organic phase was washed with brine (1.00 L), dried over anhydrous Na2SO4 and concentrated in vacuo. Without purification, compound 2 (about 385 g) was obtained as a yellow oil.

[0529] 1.2 Preparation of compound 2A

[0530] At 0-15 ℃, DMAP (19.8g, 162mmol) was added to a pyridine (1.75L) solution of compound 4 (350g, 1.62mol, HCl) and Ac2O (994g, 9.74mol, 912mL) at a disposable rate and TEA (164g, 1.62mol, 226mL) was added dropwise. The mixture was stirred at 25 ℃ for 16 hours. LCMS (product: RT=0.687min) showed that the starting reactants were completely consumed. EtOAc (1.40L) was added to the mixture at 25 ℃ and stirred for 30 minutes, then the mixture was filtered and the filter cake was washed with EtOAc (300mL). The filter cake was ground with water (1.45L) for 30 minutes at 25 ℃. The mixture was filtered and the filter cake was washed with water (175mL x 3), and the filter cake was collected to obtain compound 2A (about 580g) as a white solid.

[0531] 1.3 Preparation of compound 2B

[0532] Three reactions were performed in parallel.

[0533] To a solution of compound 2A (200 g, 514 mmol) in DCM (800 mL) was added TMSOTf (137 g, 616 mmol, 111 mL) dropwise at 10-15° C. over 0.5 h. The mixture was then stirred at 25° C. for 3 h. TLC (dichloromethane:methanol=20:1) showed that compound 2A (R f =0.54) is completely consumed and the new point (R f =0.24) was formed. The three reactions were combined. The mixture was cooled to 0-15°C and slowly poured into a solution of NaHCO3 (300 g dissolved in 3.00 L water) at 0-5°C. The organic phase was separated and the aqueous phase was extracted with DCM (1.00 L x 3). The organic layers were combined, dried over Na2SO4, filtered and concentrated in vacuo. Without purification, compound 2B (approximately 507 g) was obtained as a yellow oil and used in the next step.

[0534] 1.4 Preparation of compound 3

[0535] To a mixture of compound 2B (250 g, 759 mmol) and compound 2 (151 g, 531 mmol) in DCM (1.00 L) was added TMSOTf (84.4 g, 380 mmol, 69.0 mL) dropwise at 0-10° C. and the mixture was stirred at 20° C. for 12 hours. TLC (dichloromethane:methanol=20:1) showed that compound 2 (R f =0.33) is completely consumed and a new point is formed (R f=0.03). The combined reaction was cooled to 0-5°C and then poured into NaHCO (aqueous solution, 100 g dissolved in 1 L of water) and stirred at 5-10°C for 10 minutes. The phases were separated. The aqueous phase was extracted with DCM (500 mL x 2), the combined organic phases were dried over NaSO, filtered, and the filtrate was concentrated in vacuo. Without purification, compound 3 (approximately 360 g) was obtained as a yellow oil.

[0536] 1 H NMR: (400 MHz, DMSO).

[0537] δ=7.79-7.37(m,1H),7.35-7.26(m,5H),5.21-5.20(m,1H),5.00-4.95(m,3H),4.55-4.53(m,1H),4.03-3.86(m,3H),3.61-3.59(m,1H) ,3.59-3.57(m,1H),3.48-3.40(m,6H),3.39-3.31(m,2H),3.14-3.13(m,2H),2.09(s,3H),1.99(s,3H),1.88(s,3H),1.76-1.74(m,3H).

[0538] 1.5 Preparation of Intermediate 3-4 (TFA Salt)

[0539] Three reactions were performed in parallel.

[0540] To a mixture of Pd / C (18.0 g, 16.3 mmol, 10% content) in THF (1.80 L) was added compound 3 (180 g, 293 mmol) and TFA (33.5 g, 293 mmol, 21.8 mL) under an argon atmosphere. The suspension was vented and vented three times with hydrogen. The mixture was stirred at H2 (50 Psi) and 30 ° C for 2 hours. LCMS (product: RT = 0.697 min) showed that compound 3 was consumed and a product peak was detected. The three reactions were combined. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to remove the solvent. Intermediate 3-4 (TFA salt) (393 g, 660 mmol, 74.8% yield, 99.6% purity, TFA) was obtained as a yellow solid without purification.

[0541] 1 H NMR: (400 MHz, DMSO-d6)

[0542] δ=7.92(d,J=9.1Hz,4H),5.27-5.17(m,1H),5.03-4.91(m,1H),4.60-4.50(m,1H),4.09-3.97(m,4H),3.85(s ,2H),3.65-3.46(m,10H),3.04-2.92(m,2H),2.10(s,3H),2.00(s,3H),1.94-1.86(m,3H),1.82-1.71(m,4H).

[0543] 2. Preparation of Intermediates 3-5

[0544] 2.1 Preparation of compound 5

[0545] To a solution of compound 4B (10.0 g, 35.5 mmol, 1.00 eq) and compound 3-4 (46.3 g, 78.2 mmol, 2.20 eq, TFA) prepared above in DCM (1.00 L) was added DIEA (30.3 g, 234 mmol, 40.8 mL, 6.60 eq) in one portion at 25°C. The mixture was stirred for half an hour at 25°C. HBTU (30.3 g, 234 mmol, 40.8 mL, 6.60 eq) was added to the mixture. The mixture was stirred at 25°C for 16 hours. LCMS (product: RT = 0.681 mins) indicated the reaction was complete, and the mixture was concentrated in vacuo. At 20 ℃, 0.50N HCl (200mL x 2) was added to the mixture, and extracted with DCM (3x 500mL), the combined organic layers were washed with saturated NaHCO (3x 800mL) until pH=8, washed with brine (3x 500mL), and dried and concentrated in vacuo to purify. The residue was purified by column chromatography (SiO , DCM:MeOH=50:1-15:1). The residue was concentrated in vacuo at 40 ℃ and purified by preparative-MPLC (column: 800g Agela C18; mobile phase: [water-ACN]; 15-45% 25min; 45% 10min). Vacuum drying was used to obtain compound 5 (approximately 180g+75.0g+87.0g+40.0g+38.0g) as a yellow solid.

[0546] 417.0 g of compound 3-4 was converted into compound 5 through 9 batches.

[0547] 2.2 Preparation of intermediate 3-3

[0548] Compound 5 (73.0 g, 61.7 mmol, 1.00 eq) and TFA (7.04 g, 61.7 mmol, 4.57 mL, 1.00 eq) were added to a solution of Pd / C (3.00 g, 10% content) in THF (300 mL) under an argon atmosphere. The suspension was degassed and purged with hydrogen three times. The mixture was stirred at 20°C under H2 (20 Psi) for 16 hours. TLC (dichloromethane:methanol = 8:1, R f =0.0) indicated that the reaction was complete. The mixture was filtered through celite, and the filtrate was concentrated under pressure to remove the solvent to obtain compound 3-3 (about 33.4 g + 129 g + 75.0 g) as a white solid.

[0549] 1 H NMR: (400 MHz, DMSO)

[0550] δ=8.53(t,J=5.2Hz,1H),8.18(d,J=2.4Hz,3H),8.03(t,J=5.2Hz,1H),7.84(dd,J=3.6H z,2H),5.22(d,J=3.2Hz,2H),4.96(dd,J=3.2Hz,2H),4.55(d,J=8.4Hz,2H),4.02(t,J= 8.8Hz,6H),3.77-3.59(m,5H),3.58-3.45(m,21H),3.40-3.20(m,4H),2.18(t,J=7.6Hz ,2H),2.17(d,J=8.0Hz,6H),2.10(s,6H),1.99(s,6H),1.90-1.80(m,8H),1.77(s,6H).

[0551] 3. Preparation of Compound E7

[0552] 3.1 Preparation of compound 3

[0553] Compound 1 (2.00 g, 1.87 mmol, prepared according to the method for Intermediate 3-3 above) was dissolved in DCM (20.0 mL) at room temperature. DIEA (0.135 mL, 0.814 mmol) and compound 2 (0.550 g, 0.814 mmol) were added sequentially to the solution, and the nitrogen atmosphere was replaced three times. The reaction mixture was stirred at 25°C for 16 hours. LC-MS / MS detected the product's MS response, and thin-layer chromatography (dichloromethane / methanol = 5 / 1) showed the disappearance of the starting material and the formation of new spots. The reaction solution was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography (dichloromethane / methanol = 5 / 1) to afford compound 3 (approximately 780 mg) as a white solid.

[0554] 1H NMR (400 MHz, CD3OD)

[0555] δ=7.28-7.42(m,5H),5.30-5.34(m,4H),5.04-5.14(m,6H),4.63-4.67( m,4H),4.36-4.44(m,2H),4.00-4.20(m,23H),3.91-3.95(m,4H),3.69-3 .77(m,9H),3.52-3.67(m,32H),3.34-3.43(m,9H),2.29-2.31(m,4H),2. 14(s,12H),2.03(s,12H),1.92-1.96(m,24H).LCMS:m / z=1221.6(M / 2+H) + .

[0556] 3.2 Preparation of compound 4

[0557] Compound 3 (1.10 g, 0.451 mmol) was dissolved in MeOH (10.0 mL) at room temperature. 10% wet Pd / C (0.050 g, 0.451 mmol) was added to the solution. The hydrogen atmosphere was replaced three times, and the reaction mixture was stirred at 25°C for 18 hours under a hydrogen atmosphere (14.696 psi). Liquid chromatography-mass spectrometry (LC-MS / MS) detected the product. Thin-layer chromatography (dichloromethane / methanol = 10 / 1, phosphomolybdic acid) revealed complete consumption of the starting material and the formation of new spots. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to yield compound 4 (approximately 840 mg) as a white solid.

[0558] 1 H NMR (400 MHz, CD3OD)

[0559] δ=5.32-5.34(m 4H),5.06-5.10(m,4H),4.63-4.65(m,4H),4.38-4.40(m,2H),3.99-4.20(m,20H),3.90-3.97(m,4H),3.69-3.76(m,6H),3.50-3 .68(m,36H),3.35-3.44(m,11H),2.28-2.38(m,4H),2.15(s,12H),2.03(s,12H),1.90-1.94(m,24H).LCMS:m / z=1154.7(M / 2+H) + .

[0560] 3.3 Preparation of compound 6

[0561] Compound 5 (232 mg, 0.364 mmol) was dissolved in DCM (10.0 mL) at room temperature. HBTU (207 mg, 0.546 mmol), DIEA (0.181 mL, 1.09 mmol), and compound 4 (840 mg, 0.364 mmol) were added sequentially to the solution, and the atmosphere was purged with nitrogen three times. The reaction mixture was stirred at 25°C for 1 hour. LC / MS analysis revealed the disappearance of the starting material, while thin-layer chromatography (dichloromethane / methanol = 5 / 1) showed the disappearance of the starting material and the formation of new spots. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography (dichloromethane / methanol = 8 / 1 to 5 / 1) to afford compound 6 (approximately 620 mg) as a white solid.

[0562] 1 H NMR (400 MHz, CD3OD)

[0563] δ=7.41-7.43(m,2H),7.23-7.34(m,7H),6.83-6.90(m,4H),5.31-5.35(m,4H),5.01-5.12(m ,4H),4.63-4.65(m,4H),4.41-4.45(m,2H),4.31-4.33(m,1H),3.99-4.22(m,22H),3.87-3.9 7(m,6H),3.58-3.81(m,45H),3.34-3.43(m,10H),2.19-2.40(m,10H),2.14(s,12H),2.02(s ,12H),1.92-1.96(mz,24H),1.48-1.63(m,4H),1.28-1.38(m,8H).LCMS:m / z=1460.0(M / 2+H) + .

[0564] 4. Preparation of Compound E7

[0565] Compound 6 (300 mg, 0.103 mmol) was dissolved in DCM (10.0 mL) at room temperature. DIEA (0.102 mL, 0.618 mmol), compound 7 (10.3 mg, 0.103 mmol), and DMAP (12.6 mg, 0.103 mmol) were added sequentially to the solution, and the atmosphere was replaced with nitrogen three times. The reaction mixture was stirred at 25°C for 2 hours. LC / MS / MS analysis confirmed the disappearance of the starting material. The reaction solution was concentrated under reduced pressure, and the resulting crude product was separated by preparative HPLC (Preparative-HPLC, column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: water-ACN; B%: 17%-57%, 5 min) to afford compound E7 (53.0 mg, yield 17.08%, purity 78.94%) as a white solid.

[0566] 1 H NMR (400 MHz, CD3OD)

[0567] δ=7.41-7.45(m,2H),7.17-7.34(m,7H),6.85-6.89(m,4H),5.32-5.36(m,4H),5.03-5.13(m,4H),4.63- 4.67(m,4H),4.38-4.47(m,2H),4.32-4.34(m,1H),4.01-4.26(m,22H),3.88-4.00(m,6H),3.77-3.81(m ,7H),3.49-3.76(m,45H),3.33-3.47(m,10H),2.56-2.62(m,2H),2.45-2.55(m,3H),2.21-2.38(m,7H), 2.14(s,12H),2.05-2.11(m,2H),2.02(s,12H),1.92-1.96(m,24H),1.47-1.68(m,4H),1.28-1.34(m,8H)

[0568] MS: m / z = 3022.36 (M+H) + .

[0569] Example 2 Preparation of siRNA

[0570] The siRNA of the present invention is prepared using the solid phase phosphoramidite method well known in the art. Specific methods can be found in, for example, PCT Publication Nos. WO2016081444 and WO2019105419, and are briefly described below.

[0571] 1. Preparation of siRNA without Ligand

[0572] 1.1 Synthesis of the positive sense chain (SS chain)

[0573] Using solid-phase phosphoramidite synthesis, a blank CPG solid support is used as the starting cycle, and nucleoside monomers are linked one by one in the 3'-5' direction according to the order of the positive strand nucleotides. Each linking step involves four steps: deprotection, coupling, capping, and oxidation or thiolation. The synthesis conditions for a 5μmol oligonucleotide are as follows:

[0574] Commercially available phosphoramidites with 2'-F, 2'-O-methyl, and other modifications were used. Nucleoside monomers were provided in 0.05 mol / L acetonitrile. The reaction conditions for each step were identical: 25°C, three deprotection cycles with 3% trichloroacetic acid in dichloromethane, two coupling reactions with 0.25 mol / L ETT in acetonitrile as the activator, and two capping reactions with 10% acetic anhydride in acetonitrile and pyridine / N-methylimidazole / acetonitrile (10:14:76, v / v / v). Oxidation reactions were performed twice with 0.05 mol / L iodine / tetrahydrofuran / pyridine / water (70 / 20 / 10, v / v / v), and two thiolation reactions with 0.2 mol / L PADS in acetonitrile / 3-methylpyridine (1 / 1, v / v).

[0575] 1.2 Synthesis of antisense strand (AS strand)

[0576] Using solid-phase phosphoramidite synthesis, a blank CPG solid support is used as the starting cycle. Nucleoside monomers are linked one by one in the 3'-5' direction according to the nucleotide arrangement of the antisense strand. Each ligation step involves four steps: deprotection, coupling, capping, and oxidation or thiolation. The synthesis conditions for a 5 μmol oligonucleotide of the antisense strand are the same as those for the sense strand.

[0577] 1.3 Oligonucleotide purification and annealing

[0578] 1.3.1 Ammonolysis

[0579] The synthesized solid phase carrier (sense chain or antisense chain) was added to a 5 mL centrifuge tube, 3% diethylamine / ammonia water (v / v) was added, and the reaction was carried out in a constant temperature water bath at 35°C for 16 hours (or in a constant temperature water bath at 55°C for 8 hours). After filtering, the solid phase carrier was washed three times with ethanol / water, each time with 1 mL. The filtrate was centrifuged and concentrated, and the crude product was purified.

[0580] 1.3.2 Purification

[0581] Purification and desalination methods are well known in the art. For example, a column packed with a strong anionic filler can be used, and elution and purification can be performed using a sodium chloride-sodium hydroxide system, with the product collected and stored in a tube. Desalination can also be performed using a gel-filled purification column, with pure water as the elution system.

[0582] 1.3.3 Annealing

[0583] According to Table 6, the sense chain (SS chain) and the antisense chain (AS chain) were mixed at a molar ratio (SS chain / AS chain = 1 / 1.05), heated in a water bath to 70-95° C., maintained for 3-5 min, naturally cooled to room temperature, and the system was lyophilized to obtain the product.

[0584] Finally, the following siRNAs were obtained as shown in Table 6: DR006925, DR006166, DR006177, DR006255, DR006257, DR006298, DR006421, DR006444, DR006445, DR006446, DR006447, DR006459, DR006560, DR006566, DR006618, DR006621, DR006652, DR006653, DR006657, and DR006658. DR006925 is an siRNA in the prior art and is used as a positive control in this application.

[0585] 2. Preparation of siRNA with Sense Strand Linked to Ligand

[0586] 2.1 Ligand-CPG Carrier Connection

[0587] Ligation of compound E7 with CPG carrier

[0588] Compound E7 (53 mg, 0.018 mmol) and HBTU (13.3 mg, 0.035 mmol) were mixed and added to acetonitrile (5 mL) and shaken to dissolve. DIEA (9.0 mg, 0.07 mmol) and DMAP (2.1 mg, 0.018 mmol) were then added and shaken to dissolve until the solution became clear. ) was added to the reaction solution, and the reaction was shaken overnight at 20°C. Samples were taken and monitored for TLC, which indicated the reaction was complete. The developing solvent was DCM / methanol = 4:1, and the color was developed with phosphomolybdic acid. Filtered using a fritted funnel, the filter cake was washed with anhydrous acetonitrile (20 mL x 5), and the filter cake was filtered under reduced pressure using an oil pump for 6 h to obtain 530 mg of an off-white solid.

[0589] Place 530 mg of the condensed product in a 50 mL round-bottom flask. Add Cap C (DMAP / acetonitrile), Cap B (N-methylimidazole / pyridine / acetonitrile), and Cap A (acetic anhydride / acetonitrile) in that order. Shake overnight at room temperature. Filter, wash the filter cake with acetonitrile (20 mL x 4). Remove the filter cake and filter under reduced pressure with an oil pump for 8 hours to obtain 200 mg of an off-white solid, which was used for solid-phase synthesis.

[0590] 2.2 Synthesis of the positive sense chain (SS chain)

[0591] Using the solid-phase phosphoramidite synthesis method, using the E7 solid support prepared above as the starting cycle, nucleoside monomers were attached one by one in the 3'-5' direction according to the order of the positive strand nucleotides. Each ligation of nucleoside monomers involved four steps: deprotection, coupling, capping, and oxidation or thiolation. The synthesis conditions for a 5 μmol oligonucleotide were as follows:

[0592] The nucleoside monomer was provided in a 0.05 mol / L acetonitrile solution. The reaction conditions for each step were the same, i.e., the temperature was 25°C, and deprotection was performed three times using a 3% trichloroacetic acid-dichloromethane solution. The coupling reaction was performed twice using a 0.25 mol / L ETT-acetonitrile solution as the activator. Capping was performed twice using 10% acetic anhydride-acetonitrile and pyridine / N-methylimidazole / acetonitrile (10:14:76, v / v / v). Oxidation was performed twice using 0.05 mol / L iodine / tetrahydrofuran / pyridine / water (70 / 20 / 10, v / v / v). Thiolysis was performed twice using 0.2 mol / L PADS in acetonitrile / 3-methylpyridine (1 / 1, v / v).

[0593] 2.3 Synthesis of antisense strand (AS strand)

[0594] Using solid-phase phosphoramidite synthesis, a blank CPG solid support is used as the starting cycle. Nucleoside monomers are linked one by one in the 3'-5' direction according to the nucleotide arrangement of the antisense strand. Each ligation step involves four steps: deprotection, coupling, capping, and oxidation or thiolation. The synthesis conditions for a 5 μmol oligonucleotide of the antisense strand are the same as those for the sense strand.

[0595] 2.4 Oligonucleotide Purification and Annealing

[0596] 2.4.1 Ammonolysis

[0597] The synthesized solid phase carrier (sense chain or antisense chain) was added to a 5 mL centrifuge tube, 3% diethylamine / ammonia water (v / v) was added, and the reaction was carried out in a constant temperature water bath at 35°C (or 55°C) for 16 hours (or 8 hours). After filtering, the solid phase carrier was washed three times with ethanol / water, each time with 1 mL. The filtrate was centrifuged and concentrated, and the crude product was purified.

[0598] 2.4.2 Purification

[0599] Purification and desalination methods are well known in the art. For example, a column packed with a strong anion filler can be used, and a sodium chloride-sodium hydroxide system can be used for elution and purification. The product can be collected and pipetted, and desalination can be performed using a gel-filled purification column, and the elution system can be pure water.

[0600] 2.4.3 Annealing

[0601] According to Table 6, the sense chain (SS chain) and the antisense chain (AS chain) were mixed at a molar ratio (SS chain / AS chain = 1 / 1.05), heated in a water bath to 70-95° C., maintained for 3-5 min, naturally cooled to room temperature, and the system was lyophilized to obtain the product.

[0602] Finally, the following siRNAs were obtained as shown in Table 6: DR007102, DR007112-DR007130, DR009198, DR009427, DR009428, and DR009197. DR007102 is an siRNA in the prior art and is used as a positive control in this application.

[0603] Example 3 Activity screening of primary human hepatocytes (PHH)

[0604] Cell transfection

[0605] Take 1.4 mL of rat tail collagen solution (Sigma, C3867), add it to 40.6 mL of distilled water without DNase and RNase, mix well, add 40 μL to each well of a 96-well culture plate, coat overnight at 4°C, and remove the coating solution the next day.

[0606] On the second day, before use, the coated cell plate was rinsed with DPBS and then the DPBS was removed. PHH cells (Shanghai Xuanyi, product number QYLF-HPMC) were revived at 37°C, added to the recovery medium, centrifuged, resuspended and counted. PHH cells were plated in a 96-well plate at 90 μL / well, 2×10 4 cells / well; complete culture medium was replaced after 4 hours, and transfection was performed after 18 hours.

[0607] On the third day, 20 μM siRNA stock solution was diluted with Opti-MEM. 198 μL Opti-MEM was added to 2 μL siRNA stock solution and pipetted to mix. This was used as the first concentration point and gradient dilution was performed according to actual experimental needs.

[0608] On the third day, dilute 0.9 μL of RNAiMAX (Thermo, 13778150) with 14.1 μL of Opti-MEM. Gently pipette to mix thoroughly, and let stand at room temperature for 5 minutes. Then, take 15 μL of the prepared RNAi-MAX mixture and 15 μL of the diluted compound and gently pipette to mix thoroughly, avoiding the introduction of bubbles. Let stand at room temperature for 10 minutes. Add 10 μL / well to a 96-well plate. Incubate in a 37°C, 5% CO2 incubator for 24 hours before extracting RNA.

[0609] RNA extraction

[0610] Cell RNA was extracted using a nucleic acid extractor (Hangzhou Aosheng, Auto-pure96) according to the operating procedures of a high-throughput cell RNA extraction kit (Fanzhi Medical, FG0412).

[0611] RNA reverse transcription

[0612] For preparation of denaturation reaction mixture, refer to PrimeScript TM II 1st Strand cDNA Synthesis Kit (Takara, 6210B). Each well contains 1 μL of Oligo dT Primer, 1 μL of dNTP Mixture, and 12.5 μL of template RNA. Denature the reaction at 65°C for 5 minutes in a conventional PCR instrument. Rapidly cool the mixture on ice for 2 minutes.

[0613] Preparation of reverse transcription reaction solution, refer to PrimeScript TM II 1st Strand cDNA Synthesis Kit (Takara, 6210B). Each well contains 4 μL of 5× PrimeScript II Buffer, 0.5 μL of RNase Inhibitor, and 1 μL of PrimeScript II RTase.

[0614] 14.5 μL of the denatured reaction solution was slowly mixed with the reverse transcription reaction solution, and the mixture was incubated at 42°C for 45 minutes in a conventional PCR instrument for reverse transcription. The enzyme was inactivated by incubation at 95°C for 5 minutes, and the reverse transcription product (cDNA) was cooled at 4°C.

[0615] After the inversion is completed, 30 μL of DNase- and RNase-free distilled water is added to the cDNA sample in each well.

[0616] Fluorescence quantitative PCR

[0617] ReferenceTaqMan TM Quantitative PCR (ABI, QuantStudio3) was performed using 20 μL of Fast Advanced Master Mix (ABI, 4444965). The reaction schedule was: (50°C, 2 minutes) × 1 cycle; (95°C, 20 seconds) × 1 cycle; (95°C, 1 second; 60°C, 24 seconds) × 40 cycles.

[0618] The information of the primers is shown in Table 7.

[0619] Table 7 Primer information

[0620] Statistics

[0621] Calculation 2 -△△Ct The values ​​were converted into percentages to obtain the residual inhibition rate;

[0622] △△Ct=[(target gene of Ct experimental group-internal reference of Ct experimental group)-(target gene of Ct control group-internal reference of Ct control group)].

[0623] The target gene was hMASP2, and the internal reference was hACTB.

[0624] The final concentration of siRNA was 10 nM, and the activity of siRNA in human primary hepatocytes was screened. The screening results are shown in Table 8.

[0625] Table 8. Results of high-throughput screening of human primary hepatocyte activity

[0626] Example 4 Activity screening of primary monkey hepatocytes (PCH)

[0627] Cell transfection

[0628] Add 100 μL of Coating Medium to each well of a 96-well cell culture plate and coat at 37°C for 30 minutes. After coating, aspirate the Coating Medium.

[0629] Monkey primary hepatocytes (PCH, CCH-100CY-PQ, purchased from Miaoshun (Shanghai) Biotechnology Co., Ltd.) were resuspended in Thawing Medium, centrifuged and counted, and plated in 96-well plates at 90 μL / well. 2 × 10 4 cells / well.

[0630] Compound dilution: Dilute the 20 μM compound stock solution with Opti-MEM. Add 2 μL of compound stock solution to 198 μL of Opti-MEM and mix by pipetting. This is used as the first concentration point.

[0631] Transfection procedure: Dilute 0.9 μL RNAiMAX (Thermo, 13778150) in 14.1 μL Opti-MEM, gently pipette to mix, and let stand at room temperature for 5 minutes. Then, take 15 μL of the prepared RNAi-MAX mixture and 15 μL of the diluted compound and gently pipette to mix, avoiding the introduction of bubbles. Let stand at room temperature for 10 minutes. Add 10 μL / well to a 96-well plate. Incubate in a 37°C, 5% CO2 incubator for 4 hours, then replace the culture medium. Extract RNA the next day.

[0632] The RNA extraction and PCR methods were the same as in Example 3, and the primers used were as follows:

[0633] Table 9 Primer information

[0634] The target gene is mkMASP2, and the internal reference is mkGAPDH.

[0635] The compound was selected with an initial concentration of 10 nM, and 10-fold dilution was performed at five concentration points (10 mM, 1 nM, 0.1 nM, 0.01 nM, 0.001 nM) to screen the activity of 34 siRNA compounds. The experimental results are shown in Table 10, where the percentage value represents the residual inhibition rate, and the calculation method is the same as Example 3.

[0636] Table 10 Results of 5-point IC50 activity screening experiment in monkey primary hepatocytes (PCH)

[0637] Example 5 Transgenic Mouse Primary Hepatocyte (PMH) Activity Screening Experiment

[0638] Free intake

[0639] Transgenic mouse primary liver cells were isolated (purchased from Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.), counted, and plated in 96-well plates at 100 μL / well, with 1 × 10 4 cells / well.

[0640] Free uptake: 10 μL of diluted compound (final concentration) was added to 90 μL Opti-MEM, mixed evenly, added to the corresponding wells, and cultured in a 37°C, 5% CO2 incubator for 24 hours.

[0641] The RNA extraction and PCR methods were the same as in Example 3, and the primers used were as follows:

[0642] Table 11 Primer information:

[0643] The target gene was hMASP2, and the internal reference was mGAPDH.

[0644] The compound was selected with an initial concentration of 20 nM and 5 concentration points (20 nM, 4 nM, 0.8 nM, 0.16 nM, 0.032 nM) were diluted 5-fold for 5-point IC50 activity screening of primary hepatocytes of transgenic mice - free uptake. The experimental results are shown in Table 12, where the percentage value represents the residual inhibition rate, and the calculation method is the same as Example 3.

[0645] Table 12 PMH 5-point IC50 activity screening test results

[0646] Example 6 Human primary hepatocyte (PHH) activity screening

[0647] Referring to the method of Example 3, the compound was selected with an initial concentration of 10 nM, and 7 concentration points (10 mM, 2.5 nM, 0.625 nM, 0.156 nM, 0.039 nM, 0.00976 nM, and 0.00244 nM) were diluted 4-fold to perform siRNA compound activity screening. The experimental results are shown in Table 13.

[0648] Table 12 Results of 7-point IC50 screening experiment for human primary hepatocyte (PHH) activity

[0649] Example 7 AAV mouse pharmacodynamic activity screening

[0650] AAV virus carrying a human MASP2 gene fragment (Heyuan Bio, H27393, pAAV-TBG-hMASP2-tWPA) was injected into mice via the tail vein at a viral dose of 1 x 10^11 vg. The day of viral injection was designated as day -14 of modeling. Serum was collected from mice on D-4 / D0, and MASP2 protein was measured by ELISA (Abcam, ab278121) as a baseline for dosing and grouping. Four mice were assigned to each group. On day 0, siRNA or saline was administered subcutaneously at a dose of 3 mg / kg. Serum was collected at various time points (D7, D14, D21, D28, D42, and D49) after dosing. The results are shown in Table 13.

[0651] Table 13 Results of AAV mouse efficacy screening experiment (values ​​in the table are percentages of baseline)

[0652] Example 8 Pharmacological activity screening in Tg mice

[0653] Fifty-five MASP2 transgenic mice (Biocytogen) were divided into groups of 5 mice (3 of which were injected with DR007102) based on baseline (D0) MASP2 protein levels. SiRNA or saline were administered subcutaneously on day 0 at a dose of 3 mg / kg. Serum was collected at various time points after administration (D7, D14, D21, D28, D42, and D56) to measure MASP2 protein levels. The results are shown in Table 14.

[0654] Table 14 Results of the Tg mouse pharmacodynamic activity screening experiment (values ​​in the table are absolute MASP2 values)

Claims

1. A double-stranded nucleic acid (dsRNA) for inhibiting the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a cell, the dsRNA comprising a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand and the antisense strand are each independently 15-30 nucleotides in length, and the antisense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 22-40.

2. The dsRNA of claim 1, wherein the sense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 2-20.

3. The dsRNA of claim 1 or 2, wherein the dsRNA is siRNA.

4. The dsRNA of any one of claims 1 to 3, wherein the antisense strand has a length of 15-27 nucleotides, preferably 17-25 nucleotides, more preferably 18-23 nucleotides, more preferably 19-22 nucleotides, and most preferably 21 amino acids.

5. The dsRNA of any one of claims 1 to 4, wherein the antisense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, a nucleotide sequence of at least 18 consecutive nucleotides, a nucleotide sequence of at least 19 consecutive nucleotides, or a nucleotide sequence of at least 20 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 22 to 40, preferably the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 22 to 40.

6. The dsRNA of any one of claims 1 to 5, wherein the sense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, or a nucleotide sequence of at least 18 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 2 to 20, and preferably the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 2 to 20.

7. The dsRNA of any one of claims 1 to 6, wherein the siRNA comprises any one of the following paired sense strand sequence and antisense strand sequence: (1) Sense strand: SEQ ID NO: 2, antisense strand: SEQ ID NO: 22; (2) Sense strand: SEQ ID NO: 3, antisense strand: SEQ ID NO: 23; (3) Sense strand: SEQ ID NO: 4, antisense strand: SEQ ID NO: 24; (4) Sense strand: SEQ ID NO: 5, antisense strand: SEQ ID NO: 25; (5) Sense strand: SEQ ID NO: 6, antisense strand: SEQ ID NO: 26; (6) Sense strand: SEQ ID NO: 7, antisense strand: SEQ ID NO: 27; (7) Sense strand: SEQ ID NO: 8, antisense strand: SEQ ID NO: 28; (8) Sense strand: SEQ ID NO: 9, antisense strand: SEQ ID NO: 29; (9) Sense strand: SEQ ID NO: 10, antisense strand: SEQ ID NO: 30; (10) Sense strand: SEQ ID NO: 11, antisense strand: SEQ ID NO: 31; (11) Sense strand: SEQ ID NO: 12, antisense strand: SEQ ID NO: 32; (12) Sense strand: SEQ ID NO: 13, antisense strand: SEQ ID NO: 33; (13) Sense strand: SEQ ID NO: 14, antisense strand: SEQ ID NO: 34; (14) Sense strand: SEQ ID NO: 15, antisense strand: SEQ ID NO: 35; (15) Sense strand: SEQ ID NO: 16, antisense strand: SEQ ID NO: 36; (16) Sense strand: SEQ ID NO: 17, antisense strand: SEQ ID NO: 37; (17) Sense strand: SEQ ID NO: 18, antisense strand: SEQ ID NO: 38; (18) sense strand: SEQ ID NO: 19, antisense strand: SEQ ID NO: 39; and (19) Sense strand: SEQ ID NO: 20, antisense strand: SEQ ID NO:

40.

8. The dsRNA of any one of claims 1 to 7, wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, or all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.

9. The dsRNA of claim 8, wherein the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, and phosphorothioate internucleotide linkage modifications.

10. The dsRNA of claim 8, wherein the sense strand and / or antisense strand comprises SCP modified nucleotides.

11. The dsRNA of any one of claims 8 to 10, wherein the 3' end and / or the 5' end of the sense strand and / or the antisense strand comprises 1-5 phosphorothioate internucleotide linkages, preferably 2-3 phosphorothioate internucleotide linkages.

12. The dsRNA of any one of claims 1-11, wherein the antisense strand has a length of 21 nucleotides and has (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and 21, and 2'-fluoro modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; and / or (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

13. The dsRNA of any one of claims 1-11, wherein the antisense strand has a length of 21 nucleotides and has (i) SCP modification at position 1 (counting from the 5' end); (ii) 2'-fluoro modifications at positions 2, 4, 6, 8, 10, 12, 14, 16 and 18 (counting from the 5' end); (iii) 2'-O-methyl modifications at positions 3, 5, 7, 9, 11, 13, 15, 17, 19, 20 and 21 (counting from the 5' end); and / or (iv) (counting from the 5' end) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21.

14. The dsRNA of any one of claims 1-11, wherein the antisense strand has a length of 21 nucleotides and has (i) 2'-deoxy modifications at positions 2, 5, 7 and 12 (counting from the 5' end); (ii) SCP modification at position 1 (counting from the 5' end); (iii) 2'-fluoro modification at position 14 (counting from the 5' end); (iv) 2'-O-methyl modifications at positions 3, 4, 6, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20 and 21 (counting from the 5' end); and / or (v) Phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

15. The dsRNA of any one of claims 1-11, wherein the sense strand has a length of 19 nucleotides and has: (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19, and 2'-fluoro modified nucleotides at positions 7-9; and / or (ii) Phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, and between nucleotide positions 18 and 19 (counting from the 5' end).

16. The dsRNA of any one of claims 1-11, wherein the sense strand has a length of 19 nucleotides and has: (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19, and 2'-fluoro modified nucleotides at positions 7-9; and / or (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 17 and 18, and between nucleotide positions 18 and 19 (counting from the 5′ end).

17. The dsRNA of any one of claims 1-14 and 16, wherein the antisense strand is selected from any one of the modified nucleotide sequences shown in SEQ ID NOs: 100-122, and / or the sense strand is selected from any one of the modified nucleotide sequences shown in SEQ ID NOs: 80-98.

18. The dsRNA of any one of claims 17, wherein the dsRNA comprises any one of the following paired modified sense strand sequences and modified antisense strand sequences: Sense strand: SEQ ID NO: 80, antisense strand: SEQ ID NO: 100; Sense strand: SEQ ID NO: 81, antisense strand: SEQ ID NO: 101; Sense strand: SEQ ID NO: 82, antisense strand: SEQ ID NO: 102; Sense strand: SEQ ID NO: 83, antisense strand: SEQ ID NO: 103; Sense strand: SEQ ID NO: 84, antisense strand: SEQ ID NO: 104; Sense strand: SEQ ID NO: 85, antisense strand: SEQ ID NO: 105; Sense strand: SEQ ID NO: 86, antisense strand: SEQ ID NO: 106; Sense strand: SEQ ID NO: 87, antisense strand: SEQ ID NO: 107; Sense strand: SEQ ID NO: 88, antisense strand: SEQ ID NO: 108; Sense strand: SEQ ID NO: 89, antisense strand: SEQ ID NO: 109; Sense strand: SEQ ID NO: 90, antisense strand: SEQ ID NO: 110; Sense strand: SEQ ID NO:91, antisense strand: SEQ ID NO:111; Sense strand: SEQ ID NO: 92, antisense strand: SEQ ID NO: 112; Sense strand: SEQ ID NO: 93, antisense strand: SEQ ID NO: 113; Sense strand: SEQ ID NO: 94, antisense strand: SEQ ID NO: 114; Sense strand: SEQ ID NO: 95, antisense strand: SEQ ID NO: 115; Sense strand: SEQ ID NO: 96, antisense strand: SEQ ID NO: 116; Sense strand: SEQ ID NO: 97, antisense strand: SEQ ID NO: 117; and Sense strand: SEQ ID NO:98, antisense strand: SEQ ID NO:

118.

19. The dsRNA of any one of claims 1-15, wherein the dsRNA is further conjugated to a ligand moiety comprising N-acetylgalactosamine, preferably the sense strand is conjugated to the ligand moiety.

20. The dsRNA of claim 19, wherein the ligand is GL6, and the GL6 has the following structure: in It indicates the position linked to the sense strand of the dsRNA (preferably the 3' end of the sense strand) via a phosphate group or a phosphorothioate group.

21. The dsRNA of claim 20, wherein the antisense strand comprises any one modified nucleotide sequence selected from the group consisting of SEQ ID NOs: 100-122, and / or the sense strand comprises any one modified nucleotide sequence selected from the group consisting of SEQ ID NOs: 60-78.

22. The dsRNA of claim 21, wherein the dsRNA comprises any one of the following paired modified sense strand sequences and modified antisense strand sequences: Sense strand: SEQ ID NO: 60, antisense strand: SEQ ID NO: 100; Sense strand: SEQ ID NO: 61, antisense strand: SEQ ID NO: 101; Sense strand: SEQ ID NO: 62, antisense strand: SEQ ID NO: 102; Sense strand: SEQ ID NO: 63, antisense strand: SEQ ID NO: 103; Sense strand: SEQ ID NO: 64, antisense strand: SEQ ID NO: 104; Sense strand: SEQ ID NO: 65, antisense strand: SEQ ID NO: 105; Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 106; Sense strand: SEQ ID NO: 67, antisense strand: SEQ ID NO: 107; Sense strand: SEQ ID NO: 68, antisense strand: SEQ ID NO: 108; Sense strand: SEQ ID NO: 69, antisense strand: SEQ ID NO: 109; Sense strand: SEQ ID NO: 70, antisense strand: SEQ ID NO: 110; Sense strand: SEQ ID NO: 71, antisense strand: SEQ ID NO: 111; Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 112; Sense strand: SEQ ID NO: 73, antisense strand: SEQ ID NO: 113; Sense strand: SEQ ID NO: 74, antisense strand: SEQ ID NO: 114; Sense strand: SEQ ID NO: 75, antisense strand: SEQ ID NO: 115; Sense strand: SEQ ID NO: 76, antisense strand: SEQ ID NO: 116; Sense strand: SEQ ID NO: 77, antisense strand: SEQ ID NO: 117; Sense strand: SEQ ID NO: 78, antisense strand: SEQ ID NO: 118; Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 119; Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 120; Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 121; and Sense strand: SEQ ID NO:66, antisense strand: SEQ ID NO:

122.

23. A cell comprising the dsRNA of any one of claims 1-22.

24. A pharmaceutical composition comprising the dsRNA of any one of claims 1 to 22, or the cell of claim 23, and optionally a pharmaceutically acceptable carrier or excipient.

25. A kit comprising the dsRNA of any one of claims 1-22, the cell of claim 23, or the pharmaceutical composition of claim 24.

26. A method of treating a disease or condition that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a subject, the method comprising the step of administering to the subject the dsRNA of any one of claims 1-22, the cell of claim 23, or the pharmaceutical composition of claim 24.

27. A method of preventing at least one symptom in a subject suffering from a disease or disorder that would benefit from reduced expression of mannan-binding lectin-associated serine protease 2 (MASP2), the method comprising the step of administering to the subject the dsRNA of any one of claims 1-22, the cell of claim 23, or the pharmaceutical composition of claim 24.

28. The method of claim 26 or 27, wherein the disease or disorder that would benefit from decreased expression of mannan-binding lectin-associated serine protease 2 (MASP2) is a MASP2-mediated or MASP2-associated disease.

29. The method of claim 28, wherein the MASP2-mediated or MASP2-associated disease is selected from the group consisting of arthritis, IgA nephropathy, thrombotic microangiopathy, venous embolism, diabetic nephropathy, and membranous nephropathy.

30. A method of reducing the level of mannan-binding lectin-associated serine protease 2 (MASP2) in a subject, the method comprising the step of administering to the subject the dsRNA of any one of claims 1-22, the cell of claim 23, or the pharmaceutical composition of claim 24.

Citation Information

Patent Citations

  • Compositions for inhibiting MASP-2 dependent complement activation

    US9011860B2

  • Targeting lipids

    WO2009082607A2

  • Modified nucleosides and oligomeric compounds prepared therefrom

    WO2011139702A2

  • Oligomer-conjugate complexes and their use

    WO2013033230A1

  • Apolipoprotein c3 (APOC3) irna compositions and methods of use thereof

    WO2016081444A1